<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306222182
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Hizentra 1 g per 5 ml PFS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN NORMAL IMMUNOGLOBULIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 25°C Don't Freez, Protect From Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        444.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CSL BEHRING" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Hizentra is</strong></p><p>Hizentra belongs to the class of medicines called human normal immunoglobulins. Immunoglobulins are also known as antibodies and are blood proteins.</p><p>&nbsp;</p><p>How Hizentra works</p><p>Hizentra contains immunoglobulins that have been prepared from the blood of healthy people. Immunoglobulins are produced by human body&rsquo;s immune system and help your body to fight infections caused by e.g. bacteria and viruses or maintain the balance in your immune system (referred to as immunomodulation). The medicine works in exactly the same way as the immunoglobulins naturally</p><p>&nbsp;</p><p>present in your blood.</p><p>&nbsp;</p><p>&nbsp;</p><p>What Hizentra is used for</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Replacement therapy</strong></p><p>Hizentra is used to raise abnormally low immunoglobulin levels in your blood to normal levels (replacement therapy). The medicine is used in the following situations:</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of adults, and children and adolescents (0-18 years) who are born with a reduced</u> <u>ability or inability to produce immunoglobulins (primary immunodeficiency syndromes). This </u>&nbsp;<u>includes conditions such as:</u></p><p>&Oslash;&nbsp; low immunoglobulin levels (hypogammaglobulinaemia) or absence of immunoglobulins (agammaglobulinaemia) in the blood</p><p>&Oslash;&nbsp; combination of low immunoglobulin levels, frequent infections and inability to produce adequate amounts of antibodies after vaccination (common variable immunodeficiency)</p><p>&Oslash;&nbsp; combination of low level or absence of immunoglobulins and absence or non-functional immune cells (severe combined immunodeficiency)</p><p>&Oslash;&nbsp; absence of certain immunoglobulin G subclasses causing recurrent infections.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Treatment of adults and children with certain kinds of blood cancer (such as multiple myeloma </u>&nbsp;<u>(MM) or chronic lymphocytic leukaemia (CLL)) which lead to severely low immunoglobulin</u> <u>levels in the blood and cause recurrent infections.</u></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Immunomodulatory therapy in CIDP patients</p><p>Hizentra is also used in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a form of autoimmune disease. CIDP is characterized by chronic inflammation of the peripheral nerves that causes muscle weakness and/or numbness mainly in the legs and arms. It is believed that the body&rsquo;s defense attack underlines such inflammation, and immunoglobulins present in Hizentra help to protect the nerve from being attacked (immunomodulatory therapy).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do <strong><u>NOT</u> </strong>infuse Hizentra:</p><p>&Oslash;&nbsp; if you were allergic to human immunoglobulins, polysorbate 80 or L-proline in the past.</p><p>&nbsp;</p><p>ETell your doctor or healthcare professional prior to treatment if you have experienced intolerance against one of these components earlier.</p><p>&Oslash;&nbsp; if you suffer from hyperprolinaemia (a genetic disorder causing high levels of the amino acid proline in the blood).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>ETalk to your doctor or healthcare professional before using Hizentra.</p><p>&nbsp;</p><p>&nbsp;</p><p>Route of administration</p><p><u>Administer Hizentra via the subcutaneous route <strong>only </strong>(under the skin).</u> If Hizentra is accidentally administered into a blood vessel, you could develop severe allergic reaction (anaphylactic shock). The infusion rate recommended by your doctor should be adhered to. Closely monitor and carefully observe for any adverse events throughout the infusion period.</p><p>&nbsp;</p><p>Hypersensitivity / Anaphylaxis</p><p>You may be allergic (hypersensitive) to immunoglobulins without knowing it. However, true allergic reactions are rare. They may occur even if you received human immunoglobulins previously and tolerated them well. It may happen particularly if you do not have enough of the immunoglobulin type A (IgA) in your blood (IgA deficiency).</p><p>ETell your doctor prior to treatment if you have an immunoglobulin type A (IgA) deficiency. Hizentra contains residual amounts of IgA which might cause an allergic reaction.</p><p>In these rare cases allergic reactions, such as a sudden fall in blood pressure or shock, may occur (see also section 4).</p><p>EIf you notice such signs during the infusion of Hizentra, stop the infusion and contact your doctor or go to the nearest hospital immediately.</p><p>&nbsp;</p><p>Your doctor will avoid potential complications by ensuring:</p><p>&Oslash;&nbsp; that you are not sensitive to human normal immunoglobulin.</p><p>&Oslash;&nbsp; the medicine must be infused slowly at first.</p><p>&Oslash;&nbsp; that you are carefully monitored for any symptoms throughout the infusion period, especially if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you receive human normal immunoglobulin for the first time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have switched from a different medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; there has been a long interval (more than eight weeks) since the previous infusion.</p><p>In these cases, it is recommended that you are monitored during the first infusion and for an hour</p><p>&nbsp;</p><p>afterwards. If the points above do not apply for you it is recommended that you are observed for at least 20 minutes after administration.</p><p>&nbsp;</p><p>Blood clots</p><p>ETell your doctor if you have a history of heart or blood vessel disease or blood clots, have thick blood, or have been immobile for some time. These things may increase your risk of having a blood clot after using Hizentra. Also tell your doctor what drugs you are using, as some drugs, such as those that contain the hormone estrogen (for example, birth control pills), may increase your risk of developing a blood clot. Contact your doctor immediately if you experience signs and symptoms such as shortness of breath, chest pain, pain and swelling of a limb, weakness or numbness on one side of the body after receiving Hizentra.</p><p>&nbsp;</p><p>Aseptic Meningitis Syndrome (AMS)</p><p>EContact your doctor if you experience the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting after receiving Hizentra. These symptoms might indicate aseptic meningitis (a temporary and reversible non-infectious inflammation of the protective membranes surrounding the brain and spinal cord). Your doctor will decide if further tests are necessary and whether Hizentra should be continued.</p><p>&nbsp;</p><p>Renal complications</p><p>ETell your doctor if you have or had previously problems with your kidneys, take medicinal products that may harm your kidneys (nephrotoxic medicinal products), have diabetes (diabetes mellitus), hypovolemia (the liquid portion of your blood is too low), thick blood (hyperviscosity), are older than 65 years, or suffer from a condition called paraproteinaemia or sepsis. In these circumstances, immunoglobulin preparations, particularly those containing sucrose, may increase the risk of serious renal complications (acute renal failure, acute tubular necrosis, proximal tubulopathy, osmotic nephrosis), including rapid loss of the kidney function (acute renal failure). Hizentra does not contain sucrose.</p><p>&nbsp;</p><p>Haemolytic anaemia</p><p>Immunoglobulin products can contain blood group antibodies that may affect certain blood tests (serological tests such as e.g. DAT, direct Coombs test) and, rarely, cause the breakdown of the red blood cells (haemolysis). It has been reported that this may lead to a subsequent decrease in the red blood cells (delayed haemolytic anaemia) during the immunoglobulin therapy.</p><p>&nbsp;</p><p>Pathogen safety</p><p>&nbsp;</p><p>Hizentra is made from human blood plasma. This is the liquid part of the blood. When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include:</p><p>&Oslash;&nbsp; careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and</p><p>&Oslash;&nbsp; the testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of these medicines also include additional steps in the processing of the blood or plasma that can inactivate or remove viruses.</p><p>Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.</p><p>The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV, the AIDS virus), hepatitis B virus and hepatitis C virus (liver inflammation), and for the non-enveloped hepatitis A virus and parvovirus B19.</p><p>There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with Hizentra and it is also assumed that the antibody content makes an important contribution to the viral safety.</p><p>EIt is strongly recommended that every time you receive a dose of Hizentra the name and batch number of the product are recorded in order to maintain a record of the batches used (see section 3).</p><p>&nbsp;</p><p>Other medicines and Hizentra</p><p>ETell your doctor if you are using, have recently used or might use any other medicines. You must not mix other medicines with Hizentra.</p><p>&nbsp;</p><p>Live attenuated virus vaccines</p><p>ETell your vaccinating doctor prior to a vaccination about your treatment with Hizentra. Hizentra may impair the effect of some live virus vaccines such as measles, rubella, mumps and chicken pox. Therefore, after receiving this medicine you may have to wait up to 3 months before</p><p>receiving your live-attenuated vaccine. In the case of measles vaccinations the impairment may persist for up to 1 year.</p><p>&nbsp;</p><p>Blood tests</p><p>After receiving Hizentra, the results of certain blood tests (serological tests) may be impaired for a certain time.</p><p>ETell your doctor about your treatment with Hizentra prior to any blood test.</p><p>&nbsp;</p><p>Pregnancy, breastfeeding and fertility</p><p>ETell your doctor if you are pregnant, plan to become pregnant or are breastfeeding. Your doctor will decide whether you can receive Hizentra during your pregnancy or while you are breastfeeding.</p><p>No clinical studies have been performed with Hizentra in pregnant women. However, medicines that contain immunoglobulins have been used in pregnant or breastfeeding women for years, and no harmful effects on the course of pregnancy or on the baby have been observed.</p><p>If you are breastfeeding and receive Hizentra, the immunoglobulins of the medicine can also be found in the breast milk. Therefore, your baby may be protected from certain infections.</p><p>&nbsp;</p><p>Driving and using machines</p><p>The ability to drive and operate machines may be impaired by some side effects associated with Hizentra. If you experience adverse reactions during treatment you should wait for these to resolve before driving or operating machines.</p><p>&nbsp;</p><p>Hizentra contains proline</p><p>You <strong><u>must not</u> </strong>take it if you suffer from hyperprolinaemia (see also section 2). Please tell your doctor prior to treatment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Dosage</p><p>Your doctor will calculate the correct dose for you taking into account your weight and response to treatment.</p><p>Do not change the dose or dosing interval without consulting with your doctor.</p><p>If you think you should receive Hizentra more or less frequently, please speak to your doctor. If you think you have missed a dose, speak to your doctor as soon as possible.</p><p>&nbsp;</p><p>Replacement therapy</p><p>Your doctor will determine whether you need a loading dose (for adults, and children and adolescents) of at least 1 to 2.5 ml/kg of body weight that may be divided over several days. Following this, maintenance doses may be given at repeated intervals, from daily to once every two weeks, to reach a cumulative monthly dose of about 2 to 4 ml/kg of body weight. Your healthcare professional may</p><p>&nbsp;</p><p>adjust the dose based on your response to the treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>Immunomodulatory therapy</p><p>Your doctor will initiate the therapy with Hizentra 1 week after your last intravenous immunoglobulin infusion by administrating under the skin (subcutaneously) a weekly dose of 2.0 ml/kg of body weight. Your doctor will determine your weekly Hizentra dose (for adults, and children and adolescents). The weekly maintenance doses may be divided into smaller doses and administered by desired number of times per week. For dosing every two weeks, your doctor will double the determined weekly Hizentra dose. Your healthcare professional may adjust the dose based on your response to the treatment.</p><p>&nbsp;</p><p>Method and route of administration</p><p>In case of home treatment, this will be initiated and initially monitored by a healthcare professional experienced in the treatment of immunodeficiency/CIDP and in the guidance of patients for home treatment.</p><p>&nbsp;</p><p>You will be instructed in:</p><p>&Oslash;&nbsp; aseptic infusion techniques</p><p>&Oslash;&nbsp; the keeping of a treatment diary, and</p><p>&Oslash;&nbsp; measures to be taken in case of severe side effects. <u>Only after such guidance should you follow the instructions below.</u></p><p>&nbsp;</p><p>Infusion site(s)</p><p>&Oslash;&nbsp; Administer Hizentra <strong><u>under the skin only</u></strong>.</p><p>&Oslash;&nbsp; You may infuse Hizentra into sites such as abdomen, thigh, upper arm, and lateral hip (see Figure 1). If large doses are given (&gt; 50 ml), try to administer them at multiple sites.</p><p>&Oslash;&nbsp; There is no limit to the number of infusion sites used at the same time.</p><p>&Oslash;&nbsp; More than one infusion device can be used simultaneously.</p><p>&Oslash;&nbsp; The volume of product infused into a particular site may vary.</p><p>&Oslash;&nbsp; Infusion sites should be at least 5 cm <em>[at least 2 inches] </em>apart.</p><p>[Choose from the statement above the correct value and unit for the infusion site distance according to &nbsp;local requirements.]</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:206.25pt;height:141pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/user/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="275" height="188" src="data:image/png;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/wAALCAC8ARMBAREA/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/9oACAEBAAA/APfaKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKToaQuBRuzwKdRRRRRRRRRRRRRTCSO1JvPpTlOadRRRRRRRRRRRRRRUcpwvXHNUprlFbHOfSpbWXfLyeo4FXKKKKKKKKKKKKKKgL5lYA9Ka7mnW7bt3PSp6KKKKKKKKKKKKCQBknAFVGu9zbYRn/apNpZgZGJx0FNljWQ9Oah8nadwJDDoRTlvJojhxvFXoZknTch+o9KkoooooooooqOSZIh8x5PQVA08jdBtFMUgE479afxiolc2zsyLuDdRVqG5im4U4b0NTUUUUUUUUUUUVRvZC8ggU4HVqdFEFXpTytN70h61GyAmodxtphIpwM/MPatUHIBHQjIpaKKKKKKKZNIIoi5/D61SjVid8hy5/SpMCmd6lXpUUgqB493IO1h0Iq7Z3BlQpJ/rF6+9WaKKKKKKKKKQkKpY9AM1giVzeNJnIc8c9BWwMFQR0NIaZ3oI71G5xWbfTHf5fGCMHJrT0qczWQDH5k4NXqKKKKKKKqXR3TRp2HJpquHJA7U5qj71Ip4ppqCRgASabBJtuY29eK1qKKKKKKKKKr3zbbVsHBPFZ8dquQfQVJYXO+JkbqjFasvKoFNBzzSNMo4qCSQYNZ0I+1sXOMhuM1o6eoguzGOjDNatFFFFFFFZ00yeczEnngVVtZf3rgH3FXutNNOzxTS2KoXUmWVM43NipWkjV12nOwjOK2FYMoYdCKWiiiiiiiiqeo/6hF9WqBjtjY+1R6eEe33AYJY5q55S9aTIyBikeNCarzKqrxVDTyPMkAGBmr8RxfR1q0UUUUUUyU7YmOccVhXw2xgk8AYyDUFsdt9sDscIMhlxWwpyKRutL1FRynatZVy2ZoznGD160ijFxIBkgMDzx+ldBYPvtVwelWaKKKKKKKKzrqTzrkKPuR9frUcxyFVf4jUiR+TO0QGBjNWOQtR4wwzTZ22jNUJZdympJIRazRMBhXX9abPLsmVk++hzj1rZilE0SyL0YU+iiiiiqWo3HlxrEoy7n8hVG7KeV8wBwKhitWiiW7bOX45PbtWhGeKVs5pR0qvcthap21t9rlc9RGM/jVuNIyNwXk9SaksLjyrmS2cYDHKH1rUoooooooqOeTy4WYde1UljHlfN1brTYI994o6qgzTdRkdbtNgJyOQKz1vrowliDkSbc+1WBduIWL5D87c1Vknme5ijZWKsuSPWoIpXK7mVuJMZ9q6DUIvNsVZeqgEVTt7ZWYTMSTirlk22V4f4eq1eoooopsjiONnPYVlZLEyOfmbn6VVdxcXaQLzk81sXqoLMoeAMAVWjBCD6UpzmnD7tU7vOziptCwLeUH7+7mln2wXLL0DciopU3DIOGHIPpWlaTefbqx+8OGqeiiiiiiql8c+VGP4jzTZSFXngAUtguUaUj754+lVNRLJeqRtxjuazUMhtzwv+t9atgbrWUuo3AnGKps0pvYPlj+4f46hRm8pl+TmT+9zXWBA1sE7FMVRh4DIRgqcU0N5V5G3qcVqUUUUVR1GTJSAdzlvpVOdwB1wBTtJg8yVrlhwOFq5qZIsyV6g5rL/ALRZPLA53dfarNvMZy+f4ehqbnbWY92ZG2MNvJB46Vb0J8yXS5yARg+tXb+HcglAyU6/SqnVMinWEnlXbIfuyc/jWrRRRRRRVFv3t4zfwoMVBLmedYV79fYVqIoVQo6DgVQljEt04cArikSBYcjAK9uKjkx0AAHpVGVQM4UZqmLfYCxHzHvXVW7braMg5+Wq90nlyCUDhuGqtcRlk3L1HIrSgkE0COO4qSiikJCqWPQDJrGMxlleduh4X6VUCyXlwIU7n5j6CuiijWGJY0GFUYFVNSyyKg75rMbT3YwlWyF+9kdKtRwtb+YScg9DUsDrKm4fSs+SzYTBmbAyc47VNpKGLUZQGJVhwTW51GD0NZEyG2nKEfu25U1XlYqQ6/eU5FbVvMs8CyL3HNS0UUUVBNcKiFVYFzwAKquwt7fA5Y/qamsbcxJ5kn+sfk+1W6oRfNJI3q1K55NVnPNQSYPFRTRkJmtbS332Ceo4q26CRCrDg1QwyM0T9uh9RRaSi3keNzhG5U+laAIYZUgj1FLTXdY0LOwAHc1nXl0Z4NkIO3PzE1ScvKywwrlj+la1lZrZxY6yN95qtVTvsb4x3pi1HO424qLTmHkMf9o0twckYpunnGoY9VNbNRTwJcRGN/wPpWPJE8DeVKOf4W7GnWFw1szhgTGxzgdq14Z4513RtnHUelSUUVUvJmXESZyRkkdhVVXURDCYb3pY0Ml5EG5xyRWpTXOI2PtVK34jJP1qCe4iKkBuT096oC9KjYVy3Y06OVQVLkjPQ+tTXDo0e1T8wq1op/0eRfRq06q3y5RX7qetUXlJB+XIqOyupIpNxUiNjgitzqM1m3kNxKHMhHlg/KBVXeEGParmlqNjyY5JxmtCis+9P+lIPQVF5gUdRWfcXIycHim6dc4gYf7VWJJQe9Fi+dSTHpW/3oqC8UG3YkZ28iskkLzT7OGclpbdxndgg1srnaN3XvS0VBc7VjL4+boDWeJ0B5GQOlXbRCczt1bgD2q1TJf9S/0rPjOLZv8AdNY8gwYTluT6ioSCLlhkkAHrU5Mm2LKN04zUrO5lIdSvHetDRP8AVzf7wrVpksYliZD3FYs0pgbY68jvU2mukrtG6g55x6GteqOpy+XAo9TzWDE81xO0SZPzYGPSunt4Vt4FjXsOTUtFZ94M3QPtVK7s/N5DMvuKyZ9PIUlpHI9KuNpu+ZHRyi7BwKR7RoznezH3qWxPl38ee/FdH3opGAZSp6GuX1JZrKRuTt6irmg3G+aSMdMZrdooqtfKzWx29RVG0smlIaQFUU8A961gAAAOgpabIMxP/umsyLm3K+oxWTPaKrJ8gBU5Jz1pYrcGOZ1XaAQAB2zVhLZnVeVXb6d6JY9rbjtHGMCr+ij/AEeRvVq06KpX1iLldynDj9aoaVbTreMzqVC9c1uVHNAk6FJBkVHbWcNoCIl5PUmrFFFZ93xdZ9qGOUrOuvu49avbdu1T/dFRygVUiGdQhx/erou9FFRT28VzEY5VyDUdpYwWSkQrjPU1Zooooooo6jHrWQnytIvoxqrc8GrVnBu0qVscsc02E/ux9Kq3L/Nj0rV0hStgpI+8SavUUUUUUUUUVQveLpfRhxUbHC1Sf95cRoP71aV2NkyHsRiqsxqCyy2pJjsM1v0UUUUUUUUUUUVmTqUvXx90jNUL04OBW3axhLJEx1WstflZ1PGDVG5J3EDvXS26BLaNR2UVJRRRRRRRRRVK/HzRN7moHHy1Bapu1OMegJrSvlzEp9GqhMvy5pulLm+Y+i1tUUUUUUUUUUUUVRmUm6Yj0rOnhL3cfXG4ZreA2gAdhis+4gxOxHes+4gOc4reh/1Ef+6KfRRRRRRRRRVW9BPlj3qB1+XIpmnwn7U8p7DAq/cLvgYenNUWQslN06Mx3jZ7itWiiiiiiiiiiiiojHliaiNuPMDehq1UciBmBqJ7cN2qeMbYwPSnUUUUUUUUUVG6bmBPamtHlcCnRRiNMAdetSdsVD5QHahIgsu4VNRRRRRRRRRRRRRRiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiv/2Q==" /></p><p>Figure 1: Possible infusion sites for Hizentra</p><p>&nbsp;</p><p>&nbsp;</p><p>Infusion rate</p><p>The recommended initial infusion rate is up to 15 ml/ hour/ site. If well-tolerated, you may gradually increase the infusion rate to 25 ml/ hour/ site for the following two infusions.</p><p>If you are a patients at a risk, as described in section 2 (see section 2), administer Hizentra at the minimum dose and infusion rate practicable.</p><p>&nbsp;</p><p>Other instructions for use</p><p>&Oslash;&nbsp; Hizentra is a ready-to-use solution (see section 5 and section 6)</p><p>&Oslash;&nbsp; Do not use solutions that are cloudy or contain particles.</p><p>&Oslash;&nbsp; Do not use solutions that have been frozen.</p><p>&Oslash;&nbsp; Administer solution which is at room temperature (25 &deg;C).</p><p>&Oslash;&nbsp; Once a blistered pre-filled syringe has been opened, use the solution immediately.</p><p>&Oslash;&nbsp; Use aseptic technique when preparing and administering Hizentra.</p><p>&Oslash;&nbsp; Record the following data in your treatment diary:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the date of administration,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the batch number of the medicine, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the infused volume, flow rate, the number and location of infusion sites.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, please ask your doctor or healthcare professional.</p><p>&nbsp;</p><p>If you use more Hizentra than you should</p><p>If you think you have had too much Hizentra, speak to your doctor as soon as possible.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you forget to use Hizentra</p><p>If you think you have missed a dose, speak to your doctor as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>&nbsp;</p><p>Side effects observed in controlled clinical studies are presented in order of decreasing frequency. Side effects observed in post-marketing are of unknown frequency:</p><p><strong>&nbsp;</strong></p><p>The following side effects are <strong>very common </strong>(affects more than 1 patient in 10):</p><p>&Oslash;&nbsp; Nasopharyngitis</p><p>&Oslash;&nbsp; Headache, including migraine</p><p>&Oslash;&nbsp; Rash</p><p>&Oslash;&nbsp; Pain related to the musculature and bones (musculoskeletal pain), including muscle spasms and muscular weakness</p><p>&Oslash;&nbsp; Reactions at the infusion site</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side effects are <strong>common </strong>(affects 1 to 10 patients in 100):</p><p>&Oslash;&nbsp; Dizziness</p><p>&Oslash;&nbsp; Increased blood pressure (hypertension)</p><p>&Oslash;&nbsp; Cough</p><p>&Oslash;&nbsp; Diarrhoea</p><p>&Oslash;&nbsp; Abdominal pain</p><p>&Oslash;&nbsp; Feeling sick (nausea)</p><p>&Oslash;&nbsp; Vomiting</p><p>&Oslash;&nbsp; Itching (pruritus)</p><p>&Oslash;&nbsp; Skin reaction such as blistering (urticaria)</p><p>&Oslash;&nbsp; Contact dermatitis</p><p>&Oslash;&nbsp; Joint pain (arthralgia)</p><p>&Oslash;&nbsp; Fever</p><p>&Oslash;&nbsp; Tiredness (fatigue), including generally feeling unwell (malaise)</p><p>&Oslash;&nbsp; Chest pain</p><p>&Oslash;&nbsp; Flu-like symptoms</p><p>&Oslash;&nbsp; Pain</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side effects are <strong>uncommon </strong>(affects 1 to 10 patients in 1.000):</p><p>&nbsp;</p><p>&Oslash;&nbsp; Hypersensitivity</p><p>&Oslash;&nbsp; Aseptic meningitis syndrome (AMS, a temporary and reversible non-infectious inflammation of the protective membranes surrounding the brain and spinal cord)</p><p>&Oslash;&nbsp; Tremor, including psychomotor hyperactivity</p><p>&Oslash;&nbsp; Fast heartbeat (tachycardia)</p><p>&Oslash;&nbsp; Flushing</p><p>&Oslash;&nbsp; Joint inflammation (arthritis)</p><p>&Oslash;&nbsp; Chills, including low body temperature</p><p>&Oslash;&nbsp; Weight loss</p><p>&Oslash;&nbsp; Results of blood tests suggesting impaired e.g. liver and kidney function</p><p>&nbsp;</p><p>In <strong>isolated cases </strong>(post-marketing experience) hypersensitivity and anaphylactic reactions of the immune system, burning sensation, sleepiness, formation of blood clots which may be carried off in the blood circulation and which may result in blockage of a blood vessel (embolic and thrombotic events), and infusion-site ulcer have been observed in treatment with Hizentra.</p><p>&nbsp;</p><p>In isolated cases (post-marketing experience with other immunoglobulins; not observed with Hizentra) haemolytic anaemia, acute renal failure, acute tubular necrosis, proximal tubulopathy and osmotic nephrosis.</p><p>&nbsp;</p><p>ETell your doctor immediately if you have any of the following signs or symptoms during or following an infusion of Hizentra:</p><p><strong>&nbsp;</strong></p><p>&Oslash;&nbsp; You may be allergic (hypersensitive) to immunoglobulins and allergic reactions such as a sudden fall in blood pressure or shock may occur (e.g. you may feel light-headed, dizzy, faint on standing, cold in the hands and feet, sense an abnormal heart beat or chest pain, or have blurred vision).</p><p>If you notice such signs during the infusion of Hizentra, tell your doctor immediately. Please see also section 2 of this leaflet about the risk of allergic reactions.</p><p>You may reduce or even avoid possible side effects if you slowly infuse Hizentra.</p><p>&Oslash;&nbsp; Pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body, sudden confusion, or trouble speaking or understanding could be signs of a blood clot.</p><p>&Oslash;&nbsp; Bad headache with nausea, vomiting, stiff neck, fever, and sensitivity to light could be signs of AMS.</p><p>&nbsp;</p><p>Side effects such as these may occur even when you have previously received human immunoglobulins and tolerated them well.</p><p>Please also refer to section 2 for additional details on circumstances which increase the risk of side effect.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your your doctor or healthcare professional. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>&Oslash;&nbsp; Do not use this medicine after the expiry date (EXP) which is stated on the outer carton and the blistered pre-filled syringe label after EXP.</p><p>&Oslash;&nbsp; Hizentra should be administered as soon as possible after opening the blistered pre-filled syringe as the solution contains no preservative.</p><p>&Oslash;&nbsp; Do not store above 25&deg;C.</p><p>&Oslash;&nbsp; Do not freeze.</p><p>&Oslash;&nbsp; Do not use if Hizentra has been frozen.</p><p>&Oslash;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&Oslash;&nbsp; Keep the blistered pre-filled syringe in the outer carton in order to protect from light.</p><p>&Oslash;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your doctor or healthcare professional how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The <strong>active substance </strong>is human normal immunoglobulin. One ml contains 200 mg of human plasma protein (20 % solution), of which at least 98% is immunoglobulin type G (IgG).</p><p>The approximate percentage of IgG subclasses is as follows: IgG<sub>1</sub> 69 %, IgG<sub>2</sub> 26 %, IgG<sub>3</sub> 3 %, IgG4 2 %.</p><p>This medicine contains trace amounts of IgA (not more than 50 micrograms/ml).</p><p>&nbsp;</p><p>The <strong>other ingredients </strong>(excipients) are L-proline, polysorbate 80, sodium hydroxide (is equivalent to</p><p>&lt;10 mmol/l of sodium), hydrochloric acid and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Hizentra is provided as a ready-to-use sterile solution in single-use pre-filled syringes. Hizentra is a clear solution for subcutaneous injection (200 mg/ml).
The colour can vary from pale-yellow to light-brown. Hizentra is available in pre-filled syringes of 5, 10, or 20 ml.
Pack sizes
Packs of 1 pre-filled syringe.


[Not all pack sizes may be marketed.]


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CSL Behring AG</p><p>Wankdorfstrasse 10</p><p>3014 Bern Switzerland</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC): SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa Website: <u>https://ade.sfda.gov.sa</u></p><p>&nbsp;</p><p>Other GCC States:</p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Council of Arab Health Ministers</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s1026" style='width:454.7pt;height:144.95pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="57746,18408" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
 <v:shape id="Graphic_x0020_3" o:spid="_x0000_s1027" style='position:absolute;
  left:72;top:72;width:57601;height:18263;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5760085,1826260" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5759920,r,1825923l,1825923,,xe" filled="f" strokeweight=".40258mm">
  <v:path arrowok="t"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_4" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:3191;top:3547;width:565;height:11227;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:11.3pt;mso-line-height-rule:exactly'><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.5pt'>-</span><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.65pt'><span style='font-size:10.0pt;
     mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
     letter-spacing:-.5pt'>-</span><span style='font-size:10.0pt;mso-bidi-font-size:
     11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:2.7pt'><span style='font-size:10.0pt;
     mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
     letter-spacing:-.5pt'>-</span><span style='font-size:10.0pt;mso-bidi-font-size:
     11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:1.05pt'><span style='font-size:10.0pt;
     mso-bidi-font-size:11.0pt;letter-spacing:-.5pt'>-</span><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:1.6pt'><span style='font-size:10.0pt;
     mso-bidi-font-size:11.0pt;letter-spacing:-.5pt'>-</span><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textbox_x0020_5" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:1015;top:15107;width:527;height:1308;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:10.25pt;mso-line-height-rule:exactly'><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Calibri",sans-serif;
     mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
     letter-spacing:-.5pt'>-</span><span style='font-size:10.0pt;mso-bidi-font-size:
     11.0pt;font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textbox_x0020_6" o:spid="_x0000_s1030" type="#_x0000_t202"
  style='position:absolute;left:5295;top:1953;width:46552;height:14459;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='margin-left:4.75pt;text-align:center;
     line-height:11.3pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:
     normal'><i style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;
     mso-bidi-font-size:11.0pt'>This<span style='letter-spacing:.45pt'> </span>is<span
     style='letter-spacing:.5pt'> </span>a<span style='letter-spacing:.5pt'> </span><span
     style='letter-spacing:-.1pt'>Medicament</span><o:p></o:p></span></i></b></p>
     <p class=MsoNormal style='margin-top:.85pt;margin-right:5.25pt;margin-bottom:
     0in;margin-left:.55pt;margin-bottom:.0001pt;line-height:106%'><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:106%;
     font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'>Medicament<span style='letter-spacing:
     2.0pt'> </span>is a product<span style='letter-spacing:2.0pt'> </span>which<span
     style='letter-spacing:1.95pt'> </span>affects<span style='letter-spacing:
     -.1pt'> </span>your health<span style='letter-spacing:1.95pt'> </span>and
     its consumption<span style='letter-spacing:1.95pt'> </span>contrary<span
     style='letter-spacing:2.0pt'> </span>to instructions<span
     style='letter-spacing:2.0pt'> </span>is dangerous<span style='letter-spacing:
     2.0pt'> </span>for you.<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:0in;margin-right:5.25pt;margin-bottom:
     0in;margin-left:.55pt;margin-bottom:.0001pt;line-height:106%'><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:106%;
     font-family:"Calibri",sans-serif;mso-bidi-font-family:"Times New Roman"'>Follow
     strictly<span style='letter-spacing:2.0pt'> </span>the doctor’s
     prescription,<span style='letter-spacing:2.0pt'> </span>the method<span
     style='letter-spacing:2.0pt'> </span>of use and the instructions<span
     style='letter-spacing:2.0pt'> </span>of the pharmacist who sold the
     medicament.<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:0in;margin-right:5.25pt;margin-bottom:
     0in;margin-left:.55pt;margin-bottom:.0001pt;line-height:102%'><span
     style='font-size:10.0pt;mso-bidi-font-size:11.0pt;line-height:102%;
     font-family:"Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'>The doctor and the pharmacist<span
     style='letter-spacing:2.0pt'> </span>are the experts<span
     style='letter-spacing:2.0pt'> </span>in medicines,<span style='letter-spacing:
     2.0pt'> </span>their<span style='letter-spacing:2.0pt'> </span>benefits
     and risks. Do not by yourself<span style='letter-spacing:2.0pt'> </span>interrupt<span
     style='letter-spacing:2.0pt'> </span>the<span style='letter-spacing:2.0pt'>
     </span>period<span style='letter-spacing:2.0pt'> </span>of treatment<span
     style='letter-spacing:2.0pt'> </span>prescribed<span style='letter-spacing:
     2.0pt'> </span>for you.<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-right:66.1pt;text-indent:.55pt;
     line-height:102%'><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
     line-height:102%;font-family:"Calibri",sans-serif;mso-hansi-font-family:
     "Times New Roman";mso-bidi-font-family:"Times New Roman"'>Do not repeat
     the same prescription<span style='letter-spacing:2.0pt'> </span>without
     consulting your doctor. Keep all medicaments<span style='letter-spacing:
     2.0pt'> </span>out of reach of children.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="608" height="194" src="file:///C:/Users/user/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:454.7pt;height:144.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>Council of Arab Health Ministers Union of Arab Pharmacists</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2019


Note: Hizentra ® is a registered trademark of CSL Behring AG in many countries.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو هايزنترا<br />ات 􀑧􀑧 ة. والجلوبيولين 􀑧􀑧 رية الطبيعي 􀑧􀑧 ة البش 􀑧􀑧 ات المناعي 􀑧􀑧 مى الجلوبيولين 􀑧􀑧 ة تُس 􀑧􀑧 ن الأدوي 􀑧􀑧 ة م 􀑧􀑧 ى فئ 􀑧􀑧 ايزنترا إل 􀑧􀑧 ي ه 􀑧􀑧 ينتم<br />المناعية تُعرَف أيضًا بالأجسام المضادة وهي من بروتينات الدم.<br />كيف يعمل هايزنترا<br />ات 􀑧􀑧 حاء. والجلوبيولين 􀑧􀑧 خاص الأص 􀑧􀑧 ن دم الأش 􀑧􀑧 يرها م 􀑧􀑧 م تحض 􀑧􀑧 ة ت 􀑧􀑧 ات مناعي 􀑧􀑧 ى جلوبيولين 􀑧􀑧 ايزنترا عل 􀑧􀑧 وي ه 􀑧􀑧 يحت<br />ة 􀑧􀑧 ى مكافح 􀑧􀑧 مك عل 􀑧􀑧 اعد جس 􀑧􀑧 ي تس 􀑧􀑧 ان، وه 􀑧􀑧 م الإنس 􀑧􀑧 ي جس 􀑧􀑧 اعي ف 􀑧􀑧 از المن 􀑧􀑧 طة الجه 􀑧􀑧 نيعها بواس 􀑧􀑧 تم تص 􀑧􀑧 ة ي 􀑧􀑧 المناعي<br />ازك 􀑧􀑧 وازن جه 􀑧􀑧 ى ت 􀑧􀑧 افظ عل 􀑧􀑧 ا تح 􀑧􀑧 ي أيضً 􀑧􀑧 ال، وه 􀑧􀑧 بيل المث 􀑧􀑧 ى س 􀑧􀑧 ات عل 􀑧􀑧 ا والفيروس 􀑧􀑧 ن البكتيري 􀑧􀑧 ة ع 􀑧􀑧 دوى الناجم 􀑧􀑧 الع<br />ا 􀑧􀑧􀑧 ل به 􀑧􀑧􀑧 ي تعم 􀑧􀑧􀑧 بط الت 􀑧􀑧􀑧 ة بالض 􀑧􀑧􀑧 نفس الطريق 􀑧􀑧􀑧 دواء ب 􀑧􀑧􀑧 ل ال 􀑧􀑧􀑧 اعي). يعم 􀑧􀑧􀑧 ديل المن 􀑧􀑧􀑧 مى بالتع 􀑧􀑧􀑧 ا يُس 􀑧􀑧􀑧 و م 􀑧􀑧􀑧 اعي (وه 􀑧􀑧􀑧 المن<br />الجلوبيولينات المناعية الموجودة في دمك بشكل طبيعي.<br />ما هي استعمالات هايزنترا<br />علاج تعويضي<br />ة 􀑧􀑧 تويات الطبيعي 􀑧􀑧 ى المس 􀑧􀑧 ك إل 􀑧􀑧 ي دم 􀑧􀑧 ة ف 􀑧􀑧 ة المنخفض 􀑧􀑧 ات المناعي 􀑧􀑧 تويات الجلوبيولين 􀑧􀑧 ع مس 􀑧􀑧 ايزنترا لرف 􀑧􀑧 تعمل ه 􀑧􀑧 يُس<br />(علاج تعويضي). يُستعمل الدواء في الحالات التالية:<br />درة 􀑧􀑧 ي الق 􀑧􀑧 دام ف 􀑧􀑧 18 سنة) الذين لديهم منذ ولادتهم نقص أو انع - -1 علاج البالغين والأطفال والمراهقين ( 0<br />على إنتاج الجلوبيولينات المناعية (متلازمات نقص المناعة الأولية). وهذا يشمل حالات مثل:<br />انخفاض مستويات الجلوبيولينات المناعية (نقص جلوبيولين جاما في الدم) أو انعدام <br />الجلوبيولينات المناعية (انعدام جلوبيولين جاما في الدم)<br />توليفة من انخفاض مستويات الجلوبيولينات المناعية، والعدوى المتكررة، وعدم القدرة على <br />إنتاج كميات كافية من الأجسام المضادة بعد التطعيم (العوز المناعي الشائع المتغير)<br />توليفة من انخفاض أو انعدام الجلوبيولينات المناعية وانعدام الخلايا المناعية أو عدم قدرتها <br />على أداء وظيفتها (العوز المناعي المشترك الوخيم)<br />انعدام فئات فرعية معينة من الجلوبيولين المناعي جي مما يسبب العدوى المتكررة. <br />دد 􀑧􀑧 وي المتع 􀑧􀑧 ورم النق 􀑧􀑧 ل ال 􀑧􀑧 دم (مث 􀑧􀑧 رطان ال 􀑧􀑧 ن س 􀑧􀑧 ة م 􀑧􀑧 -2 علاج البالغين والأطفال الذين يعانون من أنواع معين<br />تويات 􀑧􀑧􀑧 ي مس 􀑧􀑧􀑧 ديد ف 􀑧􀑧􀑧 اض ش 􀑧􀑧􀑧 ى انخف 􀑧􀑧􀑧 ؤدي إل 􀑧􀑧􀑧 ي ت 􀑧􀑧􀑧 والت ((CLL) ة􀑧􀑧􀑧 ة المزمن 􀑧􀑧􀑧 ا الليمفاوي 􀑧􀑧􀑧 أو اللوكيمي (MM)<br />الجلوبيولينات المناعية في الدم مما يسبب العدوى المتكررة.<br />CIDP العلاج بالتعديل المناعي في مرضى<br />ل 􀑧􀑧 زمن المزي 􀑧􀑧 ابي الم 􀑧􀑧 دد الالته 􀑧􀑧 يُستعمل هايزنترا أيضًا في المرضى الذين يعانون من اعتلال الأعصاب المتع<br />ي 􀑧􀑧 زمن ف 􀑧􀑧 اب م 􀑧􀑧 دوث الته 􀑧􀑧 بح CIDP ف􀑧􀑧 ة. يتص 􀑧􀑧 ة الذاتي 􀑧􀑧 راض المناع 􀑧􀑧 كال أم 􀑧􀑧 د أش 􀑧􀑧 و أح 􀑧􀑧 وه (CIDP) الين 􀑧􀑧 للمي<br />ية. 􀑧􀑧 فة أساس 􀑧􀑧 ذراعين بص 􀑧􀑧 اقين وال 􀑧􀑧 ي الس 􀑧􀑧 در ف 􀑧􀑧 لات و/ أو خ 􀑧􀑧 عف العض 􀑧􀑧 ى ض 􀑧􀑧 ؤدي إل 􀑧􀑧 ا ي 􀑧􀑧 ة مم 􀑧􀑧 اب الطرفي 􀑧􀑧 الأعص<br />ة 􀑧􀑧 ات المناعي 􀑧􀑧 اعد الجلوبيولين 􀑧􀑧 م. وتس 􀑧􀑧 ن الجس 􀑧􀑧 اعي م 􀑧􀑧 وم دف 􀑧􀑧 دوث هج 􀑧􀑧 و ح 􀑧􀑧 اب ه 􀑧􀑧 ذا الالته 􀑧􀑧 ومن المعتقد أن سبب ه<br />الموجودة في هايزنترا على حماية الأعصاب من هذا الهجوم (العلاج بالتعديل المناعي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستعمل هايزنترا<br />إذا كنت قد تعرضت سابقًا لحدوث أرجية (حساسية مفرطة) تجاه الجلوبيولينات المناعية <br />برولين. - L البشرية، أو بوليسوربات 80 ، أو<br />أخبر طبيبك أو أخصائي الرعاية الصحية قبل العلاج إذا كنت قد تعرضت سابق ا لعدم <br />تحمل أحد هذه المكونات.<br />إذا كنت تعاني من فرط برولين الدم (وهو اضطراب وراثي يؤدي إلى ارتفاع مستويات <br />الحمض الأميني برولين في الدم).<br />التحذيرات والاحتياطات<br />تحدث مع طبيبك أو أخصائي الرعاية الصحية قبل أن تستعمل هايزنترا. <br />طريقة الإعطاء<br />يتم إعطاء هايزنترا فقط بالحقن تحت الجلد. إذا تم حقن هايزنترا في وعاء دموي على سبيل الخطأ، فإنك<br />قد تتعرض لحدوث تفاعل أرجي شديد (صدمة تأقية ناتجة عن الحساسية الشديدة).<br />يجب الالتزام بمعدل التسريب الذي أوصى به طبيبك. يجب المراقبة الدقيقة والملاحظة بعناية من جهة أي<br />أحداث مناوئة طوال مدة الإعطاء بالتسريب.<br />الحساسية المفرطة/ التفاعلات التأقية (الحساسية الشديدة)<br />قد تكون لديك أرجية (حساسية مفرطة) تجاه الجلوبيولينات المناعية دون أن تعرف ذلك. غير أنه من<br />النادر أن تحدث تفاعلات أرجية حقيقية، وهي قد تحدث حتى إذا كنت قد تلقيت سابقًا جلوبيولينات مناعية<br />بشرية وتحملتها بشكل جيد. ويحدث ذلك بصفة خاصة إذا كان لديك نقص في الجلوبيولين المناعي من<br />.(IgA في دمك (نقص (IgA) النوع أ<br />يحتوي .(IgA) أخبر طبيبك قبل تلقي العلاج إذا كان لديك نقص في الجلوبيولين المناعي من النوع أ <br />مما قد يسبب حدوث تفاعل أرجي (حساسية مفرطة). IgA هايزنترا على كميات ضئيلة من<br />في هذه الحالات النادرة، قد تحدث تفاعلات أرجية (حساسية مفرطة)، مثلاً في شكل انخفاض مفاجئ<br />.( لضغط الدم أو صدمة (انظر أيضًا البند 4<br />إذا لاحظت مثل هذه العلامات أثناء تلقي حقنة هايزنترا، أوقف التسريب واتصل بطبيبك أو اذهب <br />فورً ا إلى أقرب مستشفى.<br />سيتجنب طبيبك المضاعفات الممكنة بأن يتأكد:<br />من أنك لا تعاني من حساسية تجاه الجلوبيولين المناعي البشري العادي. <br />من أن الدواء يتم حقنه ببطء في البداية. <br />من أنك تخضع للمراقبة الدقيقة من جهة أي أعراض طوال مدة الإعطاء بالتسريب، لا سيما: <br />إذا كنت تتلقى الجلوبيولين المناعي البشري العادي لأول مرة ●<br />إذا كنت قد تم تحويلك من استعمال دواء مختلف ●<br />إذا كانت قد مرت فترة طويلة (أكثر من ثمانية أسابيع) منذ الحقنة السابقة. ●<br />في هذه الحالات، يوصى بمراقبتك أثناء إعطاء الحقنة الأولى بالتسريب ولمدة ساعة بعدها. إذا لم تنطبق<br />عليك النقاط المذكورة أعلاه، فإنه يوصى عندئذ بمراقبتك لمدة 20 دقيقة على الأقل بعد إعطاء الحقنة<br />بالتسريب.<br />الجلطات الدموية<br />أخبر طبيبك إذا كان لديك تاريخ عن مرض في القلب أو الأوعية الدموية أو جلطات دموية، أو <br />زيادة في كثافة الدم، أو إذا كنت متوقف عن الحركة لبعض الوقت. هذه الأشياء قد تؤدي إلى زيادة<br />مخاطرة إصابتك بجلطة دموية بعد استعمال هايزنترا. أخبر طبيبك أيضًا عن الأدوية التي<br />تستعملها، لأن بعض الأدوية، مثل تلك المحتوية على هرمون الاستروجين (على سبيل المثال،<br />أقراص منع الحمل)، قد تزيد من مخاطرة إصابتك بجلطة دموية. اتصل بطبيبك فورًا إذا حدثت<br />لديك علامات وأعراض مثل ضيق التنفس، أو ألم في الصدر، أو ألم وتورم في أحد الأطراف، أو<br />ضعف أو خدر على جانب واحد من الجسم بعد تلقي هايزنترا.<br />(AMS) متلازمة التهاب السحايا العقيم<br />اتصل بطبيبك إذا حدثت لديك العلامات والأعراض التالية: صداع شديد، تيبس العنق، نعاس، <br />حمى، رهاب الضوء، غثيان، قيء، بعد تلقي هايزنترا. هذه الأعراض قد تشير إلى التهاب السحايا<br />العقيم (التهاب مؤقت، وقابل للعكس، وغير معدي، في الأغشية الواقية المحيطة بالمخ والنخاع<br />الشوكي). سوف يقرر طبيبك ما إذا كان من الضروري إجراء مزيد من الاختبارات وما إذا كان<br />سيستمر في إعطائك هايزنترا.<br />المضاعفات الكلوية <br />تم الإبلاغ عن حدوث تفاعلات مناوئة شديدة تؤثر على الكلى في المرضى الذين يتلقون علاجً ا <br />بالجلوبيولين المناعي، وبصفة خاصة مع المستحضرات التي تحتوي على سكروز (لا يحتوي<br />هايزنترا على أي سكروز). هذه التفاعلات تشمل الفشل الكلوي الحاد، والنخر الأنبوبي الحاد،<br />والاعتلال الأنبوبي الداني، والكلاء التناضحي. العوامل التي تزيد من مخاطرة حدوث المضاعفات<br />الكلوية تشمل، ضمن أشياء أخرى، وجود قصور كلوي مسبق، داء السكري، نقص حجم الدم، العلاج<br />المرافق بأدوية سامة للكلى، السن الذي يزيد عن 65 عامًا، التقيح، فرط لزوجة الدم، ووجود<br />بارابروتين في الدم.<br />فقر الدم الانحلالي <br />قد تحتوي مستحضرات الجلوبيولينات المناعية على أجسام مضادة لفصائل الدم والتي قد تعمل مثل <br />الهيموليسينات وتؤدي إلى تغليف خلايا الدم الحمراء بالجلوبيولين المناعي في الجسم الحي. وهذا قد<br />اختبار كومبس المباشر)، وبصفة نادرة ،DAT) يؤدي إلى تفاعل مباشر موجب مضاد للجلوبيولين<br />قد يحدث فقر دم انحلالي آجل بسبب زيادة IgG إلى انحلال الدم. عقب المعالجة بالجلوبيولين المناعي<br />احتجاز خلايا الدم الحمراء. توجد تقارير عن حدوث فقر دم انحلالي.<br />الأمان من جهة مسببات الأمراض<br />يتم تصنيع هايزنترا من بلازما دم الإنسان، وهي الجزء السائل من الدم. عندما يتم تصنيع الأدوية من دم<br />أو البلازما البشرية ، يتم اتخاذ إجراءات معيَّنة لمنع انتقال العدوى إلى المرضى. هذه الإجراءات تشمل:<br />الانتقاء الدقيق للمتبرعين بالدم والبلازما للتأكد من استبعاد أولئك الذين قد ينقلوا العدوى، <br />اختبار كل كمية من الدم المتبرع به ومجمعات البلازما من جهة علامات الفيروسات/ العدوى. <br />أيضًا يقوم صانعو هذه الأدوية باتخاذ خطوات إضافية في معالجة الدم أو البلازما بحيث يتم إبطال مفعول<br />الفيروسات أو التخلص منها.<br />ورغم هذه الإجراءات، لا يمكن أن يُستبعَد تمامًا احتمال انتقال العدوى عند إعطاء الأدوية المصنوعة من<br />دم أو البلازما البشرية. ينطبق هذا أيضًا على أي فيروسات غير معروفة أو ناشئة حديثًا أو غيرها من<br />أنواع العدوى.<br />،HIV) الإجراءات المتخذة تُعتبر فعالة ضد الفيروسات المغلفة، مثل فيروس نقص المناعة البشرية<br />الالتهاب الكبدي)، ) C وفيروس الالتهاب الكبدي ،B فيروس الإيدز)، وفيروس الالتهاب الكبدي<br />.B وفيروس بارفو 19 A والفيروسات غير المغلفة مثل فيروس الالتهاب الكبدي<br />مع B وفيروس بارفو 19 A توجد خبرة سريرية مطمئنة بشأن عدم انتقال فيروس الالتهاب الكبدي<br />هايزنترا ومن المفترض أيضًا أن المحتوى من الأجسام المضادة يساهم بشكل كبير في الأمان الفيروسي.<br />يوصى بشدة أنه في كل مرة عندما تتلقى إحدى جرعات هايزنترا، يتم تسجيل اسم المستحضر <br />.( ورقم التشغيلة من أجل الاحتفاظ بسجل للتشغيلات المستخدمة (انظر البند 3<br />الأدوية الأخرى وهايزنترا<br />أخبر طبيبك إذا كنت تستعمل حال يًا أو إذا كنت قد استعملت منذ فترة قصيرة، أو إذا كنت مزمعًا أن <br />تستعمل أي أدوية أخرى.<br />لا ينبغي أن تخلط الأدوية الأخرى مع هايزنترا.<br />اللقاحات الفيروسية الحية الموهَّ نة<br />أخبر الطبيب الذي سيقوم بتطعيمك أنك تتلقى علاجًا ب هايزنترا. <br />قد يؤدي هايزنترا إلى إضعاف تأثير بعض اللقاحات الفيروسية الحية مثل الحصبة، والحصبة الألمانية،<br />والنكاف، وجدري الدجاج. لذلك بعد تلقي هذا الدواء، قد تحتاج أن تنتظر حتى 3 شهور قبل أن تتلقى<br />تطعيمً ا بلقاح حي موهَّن. في حالة التطعيم ضد الحصبة، قد يستمر هذا الإضعاف لمدة تصل إلى سنة.<br />اختبارات الدم<br />عقب تلقي هايزنترا، قد تتأثر نتائج اختبارات معينة للدم (اختبارات المصل) لفترة معينة.<br />أخبر طبيبك أنك تتلقى علاجًا ب هايزنترا قبل أي اختبار للدم. <br />الحمل والإرضاع والخصوبة<br />أخبري طبيبك إذا كنتِ حاملا ، أو إذا كنتِ تخططين للحمل، أو إذا كنتِ مرضعة. سيقرر طبيبك ما <br />إذا كان يمكنك تلقي هايزنترا أثناء الحمل أو أثناء الإرضاع.<br />لم يتم إجراء أي دراسات سريرية على هايزنترا في النساء الحوامل. غير أنه قد تم استخدام الأدوية<br />المحتوية على الجلوبيولينات المناعية في النساء الحوامل أو المرضعات لسنوات عديدة، ولم تُلاحَ ظ أي<br />آثار ضارة على مسار الحمل أو على المولود.<br />إذا كنت مُرضعة وتتلقين هايزنترا، فإن الجلوبيولينات المناعية الموجودة في الدواء قد تُفرَ ز أيضًا في لبن<br />الثدي، وبالتالي فإنها قد تعطي حماية لطفلك من بعض أنواع العدوى.<br />قيادة السيارة وتشغيل الآلات<br />قد تضعف القدرة على القيادة أو تشغيل الآلات بسبب بعض الآثار الجانبية المرتبطة ب هايزنترا. إذا<br />حدثت لديك أي تفاعلات مناوئة أثناء العلاج، يجب أن تنتظر حتى تزول هذه التفاعلات قبل أن تستأنف<br />القيادة أو تشغيل الآلات.<br />يحتوي هايزنترا على برولين<br />ر 􀑧􀑧 اء أن تخب 􀑧􀑧 د 2). برج 􀑧􀑧 ا البن 􀑧􀑧 لا ينبغي أن تستعمل هذا الدواء إذا كنت تعاني من فرط برولين الدم (انظر أيضً<br />طبيبك قبل تلقي العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-3 كيفية استعمال هايزنترا<br />ر 􀑧􀑧 ت غي 􀑧􀑧 ك إذا كن 􀑧􀑧 ر طبيب 􀑧􀑧 ك. استش 􀑧􀑧 ن طبيب 􀑧􀑧 ك م 􀑧􀑧 اة ل 􀑧􀑧 ات المُعط 􀑧􀑧 ة بالتعليم 􀑧􀑧 ا بدق 􀑧􀑧 زم دائمً 􀑧􀑧 عند استعمال هذا الدواء الت<br />متأكد.<br />الجرعة<br />سيقوم طبيبك بحساب الجرعة الصحيحة لك مع مراعاة وزنك واستجابتك للعلاج.<br />لا تغير الجرعة أو المسافة بين الجرعات دون استشارة طبيبك.<br />إذا ظننت أنك يجب أن تتلقى هايزنترا بمعدل أكثر أو أقل تكرارًا، برجاء أن تتحدث مع طبيبك.<br />إذا ظننت أنك نسيت إحدى الجرعات، تحدث مع طبيبك في أقرب وقت ممكن.<br />العلاج التعويضي<br />ى 􀑧􀑧 ل 1 إل 􀑧􀑧 ى الأق 􀑧􀑧 غ عل 􀑧􀑧 سيحدد طبيبك ما إذا كنت بحاجة إلى جرعة تحميل (للبالغين والأطفال والمراهقين) تبل<br />ات 􀑧􀑧 اء جرع 􀑧􀑧 ن إعط 􀑧􀑧 ك، يمك 􀑧􀑧 د ذل 􀑧􀑧 ام. بع 􀑧􀑧 دة أي 􀑧􀑧 ى ع 􀑧􀑧 يمها عل 􀑧􀑧 ن تقس 􀑧􀑧 ي يمك 􀑧􀑧 م والت 􀑧􀑧 ن وزن الجس 􀑧􀑧 م م 􀑧􀑧 ر/ كج 􀑧􀑧 2,5 ملليلت<br />ة 􀑧􀑧 ى جرع 􀑧􀑧 ولا إل 􀑧􀑧 بوعين، وص 􀑧􀑧 ل أس 􀑧􀑧 رة ك 􀑧􀑧 ى م 􀑧􀑧 ا إل 􀑧􀑧 دة يوميً 􀑧􀑧 رة واح 􀑧􀑧 ن م 􀑧􀑧 دءًا م 􀑧􀑧 ررة، ب 􀑧􀑧 رات متك 􀑧􀑧 ى فت 􀑧􀑧 ة عل 􀑧􀑧 المداوم<br />حية 􀑧􀑧 ة الص 􀑧􀑧 ائي الرعاي 􀑧􀑧 وم أخص 􀑧􀑧 د يق 􀑧􀑧 م. ق 􀑧􀑧 ن وزن الجس 􀑧􀑧 م م 􀑧􀑧 ر/ كج 􀑧􀑧 ى 4 ملليلت 􀑧􀑧 والي 2 إل 􀑧􀑧 غ ح 􀑧􀑧 ة تبل 􀑧􀑧 هرية تراكمي 􀑧􀑧 ش<br />بتعديل الجرعة بناءً على استجابتك للعلاج.<br />العلاج بالتعديل المناعي<br />سيبدأ الطبيب علاجك ب هايزنترا بعد أسبوع واحد من آخر حقنة من الجلوبيولين المناعي المُعطى<br />بالتسريب في الوريد، وذلك بأن يعطيك بالحقن تحت الجلد جرعة أسبوعية تبلغ 2,0 ملليلتر/ كجم من<br />وزن الجسم. سيحدد طبيبك جرعتك الأسبوعية من هايزنترا (للبالغين والأطفال والمراهقين).<br />يمكن تقسيم جرعات المداومة الأسبوعية إلى جرعات أصغر، ويتم إعطاؤها على عدد المرات المرغوبة<br />في الأسبوع. عند الإعطاء مرة كل أسبوعين، سيقوم طبيبك بمضاعفة جرعة هايزنترا المحددة للإعطاء<br />أسبوعيًا. قد يقوم أخصائي الرعاية الصحية بتعديل الجرعة بناءً على استجابتك للعلاج.<br />أسلوب وطريقة الإعطاء<br />في حالة العلاج بالمنزل، سيتم بدء العلاج ومراقبته في البداية بواسطة أخصائي رعاية صحية لديه خبرة<br />وفي توجيه المرضى لتلقي العلاج المنزلي. CIDP / في علاج نقص المناعة<br />سيتم إعطاؤك تعليمات بشأن:<br />الأساليب المعقمة لإعطاء الحقنة بالتسريب، <br />كيفية كتابة مفكرة العلاج، <br />الإجراءات التي يجب اتخاذها في حالة حدوث آثار جانبية شديدة. <br />فقط بعد تلقي هذا التوجيه، ستقوم باتباع التعليمات المذكورة أدناه.<br />موضع (مواضع) الإعطاء بالتسريب<br />يتم إعطاء هايزنترا فقط بالحقن تحت الجلد. <br />يمكنك حقن هايزنترا في أماكن مثل البطن، والفخذ، وأعلى الذراع، والجزء الجانبي من <br />الورك (انظر الشكل 1). عند إعطاء جرعات كبيرة (&gt; 50 ملليلتر)، حاول أن تحقنها في<br />أماكن متعددة<br />لا يوجد حد لعدد أماكن الإعطاء المستخدمة في آن واحد. <br />يمكن استخدام أكثر من جهاز واحد للحقن بالتسريب في آن واحد. <br />قد يتفاوت حجم المستحضر الذي يتم حقنه في مكان معين. <br />يجب أن تكون المسافة بين أماكن الحقن 5 سم على الأقل [ 2 بوصة على الأقل]. <br />[اختر من العبارة المذكورة أعلاه القيمة الصحيحة والوحدة الصحيحة للمسافة بين أماكن الحقن وفقًا<br />للمتطلبات المحلية.]<br />الشكل 1: الأماكن الممكنة لحقن هايزنترا بالتسريب<br />معدل التسريب<br />يصل معدل التسريب الابتدائي الموصى به حتى 15 ملليلتر/ ساعة/ موضع. وإذا تحملته بشكل جيد،<br />يمكنك زيادة معدل التسريب تدريجيًا حتى 25 ملليلتر/ ساعة/ موضع مع التسريبين التاليين.<br />إذا كنت من المرضى ذوي المخاطرة، كما هو موضح في البند 2 (انظر البند 2)، فيجب أن تتلقى<br />هايزنترا بأقل جرعة ممكنة وأقل معدل تسريب ممكن من الناحية العملية.<br />تعليمات أخرى خاصة بالاستعمال<br />. ( هايزنترا هو محلول جاهز للاستعمال (انظر البند 5 والبند 6 <br />لا تستخدم المحلول إذا كان غائمًا أو به جسيمات دقيقة. <br />لا تستخدم المحلول إذا كان قد تم تجميده. <br />يجب أن يكون المحلول في درجة حرارة الغرفة ( 25 &deg;م) عند استعماله. <br />بمجرد فتح السرنجة المملوءة مسبقا المغلفة ، يجب استعمال المحلول فورًا. <br />يجب اتباع أساليب التعقيم عند تجهيز وإعطاء هايزنترا. <br />سجل البيانات التالية في مفكرة علاجك: <br />تاريخ إعطاء الحقنة، ●<br />رقم تشغيلة الدواء، ●<br />الحجم الذي تم حقنه بالتسريب، ومعدل السريان، وعدد ومواضع الإعطاء بالتسريب. ●<br />إذا كانت لديك أي أسئلة أخرى عن استعمال هذا الدواء، برجاء أن تسأل طبيبك أو أخصائي الرعاية<br />الصحية.<br />إذا استعملت هايزنترا بأكثر مما ينبغي<br />إذا ظننت أنك أخذت من هايزنترا أكثر مما ينبغي، تحدث مع طبيبك في أقرب وقت ممكن.<br />إذا نسيت أن تستعمل هايزنترا<br />إذا ظننت أنك نسيت إحدى الجرعات، تحدث مع طبيبك في أقرب وقت ممكن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، فإن هذا الدواء قد يؤدي إلى حدوث آثار جانبية، غير أنها لا تحدث لجميع<br />الأشخاص.<br />الآثار الجانبية التي شوهدت في الدراسات السريرية مذكورة بالترتيب التنازلي لمعدل حدوثها. الآثار<br />الجانبية التي شوهدت في مرحلة ما بعد التسويق لا يُعرَف معدل حدوثها:<br />الآثار الجانبية التالية شائعة جدً ا ( تُصيب أكثر من 1 من بين 10 مرضى):<br />التهاب الأنف والبلعوم <br />صداع، يشمل الصداع النصفي <br />طفح <br />ألم متعلق بالعضلات والعظام (ألم هيكلي عضلي)، يشمل التشنجات العضلية وضعف <br />العضلات<br />تفاعلات في موضع الإعطاء بالتسريب <br />:( الآثار الجانبية التالية شائعة (تُصيب 1 إلى 10 مرضى من بين 100<br />دوخة <br />ارتفاع ضغط الدم <br />سعال <br />إسهال <br />ألم في البطن <br />غثيان <br />قيء <br />حكة <br />تفاعل جلدي مثلاً في شكل بثور (أرتيكاريا) <br />التهاب جلدي تماسي <br />ألم في المفاصل <br />حمى <br />تعب، يشمل الإحساس بالتوعك العام <br />ألم في الصدر <br />أعراض شبيهة بالإنفلونزا <br />ألم <br />:( الآثار الجانبية التالية غير شائعة (تُصيب 1 إلى 10 مرضى من بين 1000<br />حساسية مفرطة <br />التهاب مؤقت، وقابل للعكس، وغير معدي، في الأغشية الواقية ،AMS) التهاب السحايا العقيم <br />المحيطة بالمخ والنخاع الشوكي)<br />رعشة، تشمل فرط النشاط النفسي الحركي <br />زيادة سرعة ضربات القلب (تسرع القلب) <br />توهج <br />التهاب المفاصل <br />قشعريرة، تشمل انخفاض حرارة الجسم <br />فقدان الوزن <br />نتائج اختبارات الدم توحي بضعف وظائف الكبد والكلى على سبيل المثال <br />في حالات منعزلة (خبرة ما بعد التسويق): شوهد أثناء العلاج ب هايزنترا حدوث حساسية مفرطة،<br />تفاعلات تأقية (حساسية شديدة) بالجهاز المناعي، إحساس حارق، نعاس، تكوين جلطات دموية والتي قد<br />تنتقل في مجرى الدم وتؤدي إلى انسداد وعاء دموي (أحداث انصمامية وخثارية)، وقرحة في موضع<br />الإعطاء بالتسريب.<br />في حالات منعزلة (خبرة ما بعد التسويق مع الجلوبولينات المناعية الأخرى؛ لم تُشاهَد مع هايزنترا): فقر<br />دم انحلالي، فشل كلوي حاد، نخر أنبوبي حاد، اعتلال أنبوبي داني، كلاء تناضحي.<br />أخبر طبيبك فورًا إذا حدثت لديك أي من العلامات والأعراض التالية أثناء أو بعد تلقي حقنة <br />هايزنترا بالتسريب:<br />قد تكون لديك أرجية (حساسية مفرطة) تجاه الجلوبيولينات المناعية وقد تحدث تفاعلات <br />أرجية مثل الانخفاض المفاجئ لضغط الدم أو الصدمة (قد تشعر، على سبيل المثال، بدوخة أو<br />دوار أو إغماء عند الوقوف أو برودة في اليدين والقدمين أو خلل في ضربات القلب أو ألم في<br />الصدر أو عدم وضوح الرؤية).<br />إذا لاحظت مثل هذه العلامات أثناء تلقي حقنة هايزنترا، أخبر طبيبك على الفور. انظر أيضًا<br />البند 2 من هذه النشرة بشأن مخاطرة التفاعلات الأرجية.<br />يمكنك تقليل أو حتى تجنب الآثار الجانبية الممكنة إذا تلقيت حقنة هايزنترا ببطء.<br />قد يكون من علامات الجلطة الدموية حدوث ألم و/ أو تورم في الذراع أو الساق مع الإحساس <br />بسخونة في المنطقة المصابة، تغير لون الذراع أو الساق، ضيق في التنفس غير معروف<br />السبب، ألم أو عناء في الصدر يزداد سوءًا مع التنفس العميق، زيادة سرعة النبض بدون سبب<br />معروف، خدر أو ضعف على جانب واحد من الجسم، تشويش مفاجئ، صعوبة في الكلام أو<br />الفهم.<br />حدوث صداع شديد، مع غثيان، قيء، تيبس العنق، حمى، AMS قد يكون من علامات <br />حساسية للضوء.<br />هذه الآثار الجانبية قد تحدث حتى إذا كنت قد تلقيت سابقًا جلوبيولينات مناعية بشرية وتحملتها بشكل جيد.<br />برجاء أن تنظر أيضًا البند 2 لمزيد من التفاصيل عن الأحوال التي تؤدي إلى زيادة مخاطرة الآثار<br />الجانبية.<br />الإبلاغ عن الآثار الجانبية<br />إذا حدثت لديك أي آثار جانبية، اتصل بطبيبك أو أخصائي الرعاية الصحية. هذا يشمل أي آثار جانبية<br />ممكنة غير مذكورة في هذه النشرة. فإنك بالإبلاغ عن الآثار الجانبية قد تساعد في تقديم مزيد من<br />المعلومات عن أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كيفية تخزين هايزنترا<br />المذكور على العلبة الخارجية وعلى (EXP) لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية <br />.EXP ملصق السرنجة المملوءة مسبقا المغلفة بعد كلمة<br />يجب إعطاء هايزنترا في أقرب وقت ممكن بعد فتح السرنجة المملوءة مسبقا المغلفة وذلك لأن <br />المحلول لا يحتوي على أي مواد حافظة.<br />يُحفَظ في درجة حرارة لا تزيد عن 25 &deg;م. <br />لا ينبغي تجميده. <br />لا تستخدم هايزنترا إذا كان قد تم تجميده. <br />احفظ هذا الدواء بعيدًا عن مرأى و متناول الأطفال. <br />احفظ السرنجة المملوءة مسبقا المغلفة في العلبة الخارجية لحمايتها من الضوء. <br />لا ينبغي التخلص من أي أدوية بإلقائها في مياه الصرف أو في القمامة المنزلية. اسأل طبيبك <br />أو أخصائي الرعاية الصحية عن كيفية التخلص من الأدوية التي يتم الاستغناء عنها. هذه<br />الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات هايزنترا<br />روتين 􀑧􀑧 ن ب 􀑧􀑧 م م 􀑧􀑧 ى 200 مج 􀑧􀑧 ر عل 􀑧􀑧 وي 1 ملليلت 􀑧􀑧 ي. يحت 􀑧􀑧 ري طبيع 􀑧􀑧 اعي بش 􀑧􀑧 ولين من 􀑧􀑧 ي جلوبي 􀑧􀑧 ة ه 􀑧􀑧 ادة الفعال 􀑧􀑧 الم<br />.(IgG) البلازما البشرية (محلول 20 ٪)، منه على الأقل 98 ٪ جلوبيولين مناعي من النوع جي<br />،٪69 IgG ي: 1 􀑧􀑧 ا يل 􀑧􀑧 ي كم 􀑧􀑧 ه (IgG) ي􀑧􀑧 اعي ج 􀑧􀑧 ولين المن 􀑧􀑧 ن الجلوبي 􀑧􀑧 ة م 􀑧􀑧 ات الفرعي 􀑧􀑧 ة للفئ 􀑧􀑧 ة التقريبي 􀑧􀑧 بة المئوي 􀑧􀑧 النس<br />.٪2 IgG4 ،٪3 IgG3 ،٪26 IgG2<br />لا تزيد عن 50 ميكروجرام/ ملليلتر). ) IgA يحتوي هذا الدواء على كميات ضئيلة من<br />ل &lt; 10 􀑧􀑧 ا يقاب 􀑧􀑧 وديوم (بم 􀑧􀑧 يد ص 􀑧􀑧 وربات 80 ، هيدروكس 􀑧􀑧 رولين، بوليس 􀑧􀑧 ب - L ي􀑧􀑧 واغات) ه 􀑧􀑧 رى (الس 􀑧􀑧 ات الأخ 􀑧􀑧 المكون<br />مللي مول/ لتر صوديوم)، حمض هيدروكلوريك، ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوافر هايزنترا في شكل محلول معقم جاهز للاستعمال في سرنجات مملوءة مسبقًا لاستعمال واحد فقط.<br />هايزنترا هو محلول رائق للإعطاء بالحقن تحت الجلد ( 200 مجم/ ملليلتر).<br />قد يتفاوت اللون من أصفر شاحب إلى بني فاتح.<br />يتوافر هايزنترا في سرنجات مملوءة مسبقًا 5 أو 10 أو 20 ملليلتر.<br />أحجام العبوات<br />عبوات بها سرنجة واحدة مملوءة مسبقًا.<br />[ليس بالضرورة أن تكون جميع أحجام العبوات مطروحة في الأسواق]</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>سي إس إل بهرنج، شركة مساهمة<br />، وانكدورف ستراس 10<br />3014 بيرن، سويسرا</p><p>الإبلاغ عن الأعراض الجانبية:<br />المملكة العربية السعودية:<br />:(NPC) المركز الوطني للتيقظ و السلامة الدوائية <br />مركز الاتصال بالهيئة السعودية للغذاء والدواء: 19999 <br />npc.drug@sfda.gov.sa : البريد الإلكتروني <br />https://ade.sfda.gov.sa/ : الموقع الإلكتروني <br />دول الخليج الأخري:<br />الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة. <br />مجلس وزراء الصحة العرب<br />إن هذا دواء<br />- الدواء مستحضر يؤثر على صحتك، واستهلاكه خلاف ا للتعليمات يُعرّضك للخطر.<br />- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها<br />لك.<br />- إن الطبيب والصيدلي هما الخبيران في الدواء و بنفعه و ضرره.<br />- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<br />- لا تكرر صرف الدواء بدون استشارة الطبيب.<br />- لا تترك الأدوية في متناول أيدي الأطفال.<br />مجلس وزراء الصحة العرب<br />اتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hizentra ®
200 mg/ml solution for subcutaneous injection in pre-filled syringe

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                a.	Active substance
Human normal immunoglobulin for subcutaneous injection (SCIg).
Human plasma protein, of which at least ≥98% is immunoglobulin type G (IgG).
The approximate distribution of IgG subclasses is: IgG1 69%, IgG2 26%, IgG3 3%, IgG4 2%. The maximum immunoglobulin type A (IgA) content is 50 micrograms/mL.

b.	Excipients
L-proline, polysorbate 80, sodium hydroxide (is equivalent to <10 mmol/l of sodium), hydrochloric acid, water for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for subcutaneous injection.
1 mL contains: 200 mg of human plasma protein, of which at least 98% is IgG (20 % solution). The osmolality is approximately 380 mOsmol/kg.
The solution is clear. The colour can vary from pale-yellow to light-brown.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Replacement therapy in adults and children in:</p><p>&middot;&nbsp;&nbsp;&nbsp; Primary immunodeficiency syndromes such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; congenital agammaglobulinaemia and hypogammaglobulinaemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common variable immunodeficiency</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe combined immunodeficiency and Wiskott-Aldrich syndrome</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IgG subclass deficiencies with recurrent infections</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.</p><p>&nbsp;</p><p><strong><em>Immunomodulatory therapy:</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Hizentra is indicated for the treatment of patients with chronic inflammatory demyelinating</p><p>&nbsp;</p><p>polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenously administered immunoglobulins (IVIg).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The dose and the dosage regimen depend on the indication.</p><p>&nbsp;</p><p>&nbsp;</p><p>The therapy should be initiated and monitored under the supervision of a healthcare professional experienced in the IgG treatment of immunodeficiency or CIDP.</p><p>&nbsp;</p><p><u>Replacement therapy in adults and children</u></p><p>The dose may need to be individualised for each patient dependent on the clinical response and serum IgG trough levels. The following dose regimens are given as a guideline:</p><p>The dose regimen using the subcutaneous route should achieve a sustained level of IgG. A loading dose of at least 0.2 &ndash; 0.5 g/kg (1.0 &ndash; 2.5 mL/kg) body weight is required. This may need to be divided over several days. After steady-state IgG levels have been attained, maintenance doses are divided into smaller doses and administered at repeated intervals to reach a cumulative monthly dose in the order of 0.4 &ndash; 0.8 g/kg (2.0 &ndash; 4.0 mL/kg) body weight (see section &ldquo;Pharmacokinetics&rdquo;).</p><p>&nbsp;</p><p>For patients switching from intravenous treatment to subcutaneous therapy, the monthly dose is divided into smaller doses and administered at repeated intervals (see section &ldquo;Pharmacokinetics&rdquo;).</p><p>&nbsp;</p><p>Trough levels should be measured and assessed in conjunction with the patient&rsquo;s clinical response. Depending on the clinical response (e.g. infection rate), adjustment of the dose and/or the dose interval should be considered in order to aim for higher trough levels.</p><p>&nbsp;</p><p><u>Immunomodulatory therapy in CIDP</u></p><p>The therapy with Hizentra is initiated 1 week after the last IVIg infusion. The recommended initial subcutaneous dose is 0.4 g/kg body weight per week. If a patient is clinically stable, the Hizentra weekly dose may be reduced to a minimum of 0.2 g/kg body weight per week.</p><p>In the event of a relapse when decreasing the subcutaneous dose to 0.2 g/kg body weight per week a return should be made to the higher subcutaneous dose of 0.4 g/kg body weight per week. If the patient does not improve or relapses on the higher dose a switch should be made to IVIg, initiating with the loading dose. In the event of a rescue treatment with IVIg once, resumption of SCIg cannot be recommended.</p><p>&nbsp;</p><p>The weekly dose may be divided into smaller doses and administered at the desired frequency. When administered every two weeks, the dose of Hizentra must be doubled.</p><p>&nbsp;</p><p>Hizentra has been shown to be superior to placebo after switching from intravenous immunoglobulins (IVIg). Direct comparative data for Hizentra versus IVIg are not available.</p><p>&nbsp;</p><p><u>Posology for children and adolescents</u></p><p>The posology is determined on the basis of body weight as in adults and adjusted to the clinical outcome of the substitution therapy. Hizentra was evaluated in 54 children aged 2 to 12 years and 45 adolescents aged between 12 and &lt;18 years with PID. No paediatric-specific dose requirements were necessary to achieve the desired serum IgG levels.</p><p>Hizentra therapy in paediatric CIDP patients has not been evaluated in clinical studies.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>As the dose is administered on the basis of body weight and adjusted to the clinical outcome, it is not expected that the dose in elderly patients should differ from that in subjects aged 18 to 65 years.</p><p>Hizentra was investigated in clinical studies in 9 PID patients aged &gt;65 years. No specific dose adjustments were necessary to achieve the desired serum IgG levels.</p><p>Hizentra was investigated in clinical studies in 61 CIDP patients aged &gt;65 years. No specific dose adjustments were necessary to achieve the desired clinical outcome.</p><p>&nbsp;</p><p>Method of administration</p><p>Hizentra must be administered via the subcutaneous route only.</p><p>&nbsp;</p><p>&nbsp;</p><p>Infusion for home treatment should be commenced and initially supervised and monitored by a healthcare professional. The healthcare professional should already be experienced in supervising the home treatment of patients with primary immunodeficiency syndromes. The patient or the caregiver must be instructed in using an infusion pump, infusion techniques, how to keep a treatment diary and identifying severe adverse reactions and measures to be taken should such reactions occur.</p><p>&nbsp;</p><p>Hizentra may be injected into sites such as the abdomen, thigh, upper arm and lateral hip (see figure 1). If large doses are given (&gt; 25 mL for replacement therapy or &gt; 50 mL for CIDP) it is advisable to administer them at multiple sites. In infants and children, the infusion site should be changed after every 5-15 mL. There is no limit to the number of infusion sites. Infusion sites should be at least 5 cm apart. Several infusion sets can be used simultaneously. The volume of injected product at a given site may vary.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_1" o:spid="_x0000_s1026" style='width:253.45pt;height:174pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="32188,22098" o:gfxdata="UEsDBBQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF
95V6B8S2snG6qKrKdhb9WbZdpAeYwtimxYCApMntO3ZsqY2sbLJBwPDe+xgo1/vesB2GqJ2t+Cov
OEMrndK2rfjH5iW75ywmsAqMs1jxA0a+rq+vys3BY2SktrHiXUr+QYgoO+wh5s6jpUrjQg+JlqEV
HuQ3tChui+JOSGcT2pSlwYPX5RM2sDWJPe9p+0jy5bHl7PF4cMiquO4Hg7EgFjUBTTzRgPdGS0h0
O7Gz6oQsm6hyUo5nYqd9vCF0vpwwVP5D/Q2YdG/UzqAVsncI6RV6QhfSaP/pICihAvxQc+M8WeXn
TReoXdNoicrJbU9dzCfHGft8fKIXQjGOlyePNnOuGH9E/QsAAP//AwBQSwMEFAAGAAgAAAAhAK0w
P/HBAAAAMgEAAAsAAABfcmVscy8ucmVsc4SPzQrCMBCE74LvEPZu03oQkaa9iOBV9AHWZNsG2yRk
49/bm4ugIHibZdhvZur2MY3iRpGtdwqqogRBTntjXa/gdNwt1iA4oTM4ekcKnsTQNvNZfaARU37i
wQYWmeJYwZBS2EjJeqAJufCBXHY6HydM+Yy9DKgv2JNcluVKxk8GNF9MsTcK4t5UII7PkJP/s33X
WU1br68TufQjQpqI97wsIzH2lBTo0Yazx2jeFr9FVeTmIJtafi1tXgAAAP//AwBQSwMEFAAGAAgA
AAAhAHOnKNoaAwAA+gcAAB8AAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1s1FVNb9sw
DL0P2H8QdG8dO0ubGHWLLV2DAkUbNC12VmQlNiZLnqSkzn79qK/Eyzqs2E6DAZsWKeqRfKQurrqG
oy1TupaiwOnpACMmqCxrsS7w89PNyRgjbYgoCZeCFXjHNL66fP/uguRrRdqqpgg8CJ2TAlfGtHmS
aFqxhuhT2TIBupVUDTHwq9ZJqcgLeG54kg0GZ0lDaoEvD66uiSFoo+q/cMUl/crKKRFbosElp3l/
JWDk9N89k1xsZ6pdtHNlkdP77VyhuiwwZE6QBlKEk6AIZvCbHO1aHxx0K9VYe7laoc552dm388E6
gygsDrN0PE5HGFHQZdlgMh4EC1o9vLKPVp//sBMA+YNB6IFxokXzmxjTGONMyU2L0uNQ7Vbn4w7K
oX3gkKFZDPd/yUNbU5+FeU2P65zFHNw2ZM1Qts+Bs43F3m9c8rq9qTm3/qwcqKjewkTgRE3ZtaSb
hgnje0YxTgw0q67qVmOkctYsGdBP3ZZQHQq9aoCDraqF8ci0UczQyp6/AhyPjBoPcq+AqvRR6kDt
tzLzbAwzwjEznXwYjSb22D2/SN4qbWZMNsgKgBPOdz1Ptnc6IIkmbp8/HhyEIujWl+LXjhvGSszC
JBrua2GNYyniRu84Ev+o46CrsvTcYSf5q32XZueu6Xqh0Y0PzQKM4UADlD4wWKuiRDsRRZsAxAvM
MYJ0GCghJAWjZYGXHn5LjN1nnVoRvRwGgF1r5JY9Sac1RxMDoB20XPSt7AhxhYrTBWy9hc00HONy
vz8aFvvBcWFRpKNsOHG105LXZWS1VuvllCu0JRDVzdQ+gQI/mdkiXxNdeTunCmZc9ApPctMtXMlN
90mWOxvoEr4wZeGaMg/wWnEJaCg0E0aVVN+P116ADgXW3zZEMYz4rdBurpooqCgso6AMn0pAP3DR
WaRP3Rei2sBZA4S4l4uKtOw16npbC1TIjxsjV3XgtcdtFVybhdlxBpyEdNsXE+WcKPIIcXFiL1sm
Tp4XISNgARU4JGCj2aI9dK7PEFjY3oBPGNvJ0a0XdO6Wtldr///yBwAAAP//AwBQSwMECgAAAAAA
AAAhAF7Wll1yDQAAcg0AABsAAABjbGlwYm9hcmQvbWVkaWEvaW1hZ2UxLmpwZWf/2P/gABBKRklG
AAEBAQBnAGcAAP/bAEMAAwICAwICAwMDAwQDAwQFCAUFBAQFCgcHBggMCgwMCwoLCw0OEhANDhEO
CwsQFhARExQVFRUMDxcYFhQYEhQVFP/bAEMBAwQEBQQFCQUFCRQNCw0UFBQUFBQUFBQUFBQUFBQU
FBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFP/AABEIAHgAsAMBIgACEQEDEQH/xAAf
AAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEF
EiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJ
SlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEB
AAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIy
gQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNk
ZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfI
ycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/AP1NooooAKKKKACikZto
z2qNrpFbaSM/WgCWimxv5i5HTtTqACiiigAooooAKKKKACiio5JCh6ZoAkoqut0WIGMfWrFABRRR
QAUUUUAFFFFABRRXPa3dm8v102OTaqqHmAPLZ6L9MAn8qANC61SKWN44AZ3I2/L9386x9Y+2LMrR
OjR/T5hV9bZYYwqnAFM25Yg80AJpmvQW9tHDd5gZcjceVIzwc9q3UdZFDKwZWGQynINcxcW6TLhh
0NM0i+Gl6pHZGQfZ7kkIhP3XwSMemcH8aAOrooooAKKKKACiiobu5W0tpJnyVQZwOp9B+NAD5riO
3TfK6xr6sazJdQE9wCnESqcE8EnPp6YqlGskrma5O+dvyUf3V9v5011CyZFAEtxcSQyRy4LqrqWA
POM8/Wtq1vIbyPfDIsijrtPI+o7VkSKDEPWsiaF4ZvOicwTL92Rev0PqPY0AdpRVHRdR/tGzDsoS
ZDskVegb1Hsev41eoAKKKKACiiigArzcXMseqT6xIuE5lY4I+XIGCc44XP5da9BvpRDZXEhOAsbN
n6A1wWpAxeG3j2M5kiWMqvUg4B/TNAHYsymPdkYx61TWQNJkEYqOGxjkhVVdtgHAz2p6xRKwiC8U
ARXkyopwRXDXTXGo6sbiBiPJYbWAJCsjA9QcDv2PpxXWX1vDDG5DMT6E1z3hhdv25NpUeczqD3BO
c/jQB6dZ3H2q1hmxjzEV8emRmpazPDLiTQrLByFTb+RIx+ladABRRRQAVma+37qCP+9KGP0UE/zx
WnXG+N5nKzlCx8hFO0DPYtxweSQvbt260AS6XqBuVnDffV2X9ankPINcj4Nuj9pvIzJ5oRkXcQOT
5a5PDMD+f4CutmJ4oAnaT5B7Vja5eG2hGzl2IUfUnFaTcqCemK43xNenzoQrEFZkPHsc+o/mKAO3
8Lq0N3eRFuNqNj6Fgf6V0VeaeDZp7bWYmlaRleV4d7Y+YFnxnH/Ae7dOtel0AFFFFABRRRQBi+Ip
TceXYqcCT55f9wHp+J/lWbptu15q0McqjZCjSNjp/dX+f6VZmuBJe6hcE/KrCFfoo5/XNWfDkW62
mvHG3zz8mevljOD+PJ/EUAcsnjKy0uMwSrIXiSQ5XHRCAfxORirMfiuyaE3KBtqlVwSMndjn8Nwz
XPT6df3U7Rxqfmt50QlMBt5XGDvHpzxx3Bq5Jp9xb2OZkH2pHjZH28qAF3cb/b1H4UAZuo+MIryY
lDtRvNwu7+4cHt37V0mrWr6dHpk9qu8XFosR93Cgqf1/SuCuJbm1aJHcmRvtWFWJjje2Qf8AW/8A
6u+6vWfsovPCWntEu9ooYpU98KM/pmgCr4RM+mOLO5OftAMyqOQr/wAQH16/gfWurrjbu8FvNZ3g
PyxyKxI/ung/oTXZUAFFFFAFbUb5dOs3nYbtvCqOrMeAPzrgNVvJIYJ2kl8y6uZMgZ/iOAFHt0Fd
B4nvg19Db5zHbr5sn+8RhR+AyfxFYXh2x/4SDxAkxXda2R8xmPd/4VH8z9B60AaNxoKaH/ZqR/Mx
Rkmbuzfe3fmSPyqzI33QRzUPjrUGsL7T3QjoysDgcEZHJ/3ax/D+vT60w88Iv7kudvZt2Pw/GgDe
uGKwjHpWD4Xs49Y8TXST/chgZl9dzHbkfQZ/MVb1y+msbe3kTaVaTY24gcbSeM8dRWZ4B1I3HiyI
sQDPZyZAIPzZQ9unAPWgDTvLeSSJ4DMUuYXH7yM4ZWU5BH5ZrrNB1Q6rYh5AFuIzslUdNw7j2Iwa
yPEVgLS+W7A/d3GEc+jgcfmP1HvVPw/ef2friozYiul8s/74yVP8x+IoA7WiiigAqpqN+tnC21lN
wRiOPPJJ6celWJ2dYZDEoaTadoPQntXH+XOk00bSRmVn+eTHzdOTn659qAJvsrX00OmRMSijfczD
0zz+LH+tdJfMtnps7KAFjibavYYHAqj4ZtfJs5Ze88pcHuVACj+WfxqfX226XL7lR/48KAMvyxDZ
wrtHyj8uKyNQbzGINHiPXjpcaxiBpQIw7MM8ZbbyQOPxrj5NcuvtBtjlEcByrxsCASowMjOPm9KA
L9xp6t5sqruI/ir0HwVdfavDNk3eNTEf+AsR/ICuEt9S22s0TIh/eeVu+YHvz04+ldZ8OCToMyno
ly4H4hT/AFoAdqeni1kkgZc202TH6A91/wA9vpWh4f1MT2aW88gF3F+7ZWPzOB0YeuRj8c1a1yA3
GmTBV3OmJFA65U54/KuDv2kupIFFyiK0i/N3A9Qe3rQB6VVHUdYt9OBV23z7dywr95vT6fjT9PF1
/Z0a3ZAugu12XByem70964XxJJb6HqJD3LzTsFVpJupbk9vb+VAFUrea3cG3t1L3lyfNnY52xg9z
6AdAO+MV6BoujwaHp8drByF+Z3I5dj1Y1meB42bTJbpk2faZNy5HJUDAP55roqAOa1xFbWkJ5ZYl
x6jJb+maoXkVtZWO2KNItqlVCjGB1wKm12Ro9YumCltqJgDqeM/1Nef+IvFksjMqWl0MfwmIj9en
60Adxp8wuNDs5pDuk8sMGPXOOtUdB2r4m00dFXeka9lGw8D8v0rm9P1u4sbEWM0Fw0lpmBykTFSy
8HB6Yq/4dvjc+JNMJBQCbkH/AHTQB6le2cWoW0lvMu6Nxgjv9R7ivPNa06506Uwzltw+aGdR98Dk
EejDjivSqzPEdu0+kzFU3tHhwMc8dce+M0AQaD4kh1O1t1mYQ3rr80TcZbvt9fXHWtqvKNNvrPVN
atbUyvGDJgMnysjEHafz/ka9TtomggSNpGmZRgyPjc3ucUASVxdt4cvL/VpzchoYFkOXP8Yz0X9D
n3rtKKAEVQihVGABgAVm+JP+QPO390o35OK06ranbfbNOuoB1kiZR9SOKAPNPGljJeKJI3wPKVBw
h5DZ7qSOP7pFYVro73AlnxuVWhi+dUA5BJHyqB/AOoPXnNdNq0wk0tJemRnmrmhad5nge7uCAGeb
z1PshA/o1AGHLon2aEyFIF/eeYNqrlRzx9wevYge1dn8OU26DK3Z7lyPwAH9K5XXrrbZpg4U13Hg
u1Nr4ZsgfvSIZj/wMlv5EUAbVef+LfB94t59r02PzlkYZiUcofX6dvavQKKAGW6tHbxI53OqAMw7
nHJrndX8C2Wtasl7cSyFQQzQDoxAx16jiulooAbHGkMaxooRFG1VUcADtTqKKAOY1DC65cbhkHb+
W0VzHiO2jaNlRBuZgowPWun1pCmtvxw8SN+PI/oKwjC154g06BvuNOD/AN8gt/SgDQvLZVa4Qrgh
2z9c9awYbZY/EOl+UMH7ShOPTPNdNrUTQ6lchRkSBZPzGD+orC0eNp/F1gp/gdpDj2U0Aek0UUUA
cjJ8NtNPiKLVYpJYNjLIbdPuFgSQfYZJ4rrqKKACiiigApHbajH0GaWkZdykeoxQB55r2mSyaVFG
pw3BJrstH0pbHQLawbDBYdje5I5/Ump5dPjlXBXIq3QB51q2gM9tsyDtOP6V2+hKV0WwU9VgRT+C
gVLJYxyZ3DOTmpoYRBEqL0WgB9FFFABRRRQAUUUUAYerwGbVFOOFhA/8eNZukaaz+JY5mPy28bMB
7kbR+hNdU0CtIWIyelNt7VIC5A5bqaAMvXLUtdRSD+JNh/A5/rWPpmmNb+Jrac4wVdfzU1180KzK
Awzg5qMWiLIr4+ZTwaAJ6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACii
igAooooAKKKKAP/ZUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3RoZW1l
L3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h9oiE
hCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe/WLN
QyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRtZUX6
QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5zOqU+
Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/YWSK
cFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ526/
3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7oaJRx
LyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcILn2x
JF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0Mfrj
yTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6PwTDj
FVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXka1Hs
ALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS3/g+
IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWYVSg/
Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaPXaRQ
dL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0dlRYJ
or/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL69vfc
TTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5IhgB
UY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1hW28Y
bD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XTgFh4
ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9CbvFK+V
pHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1qdd8
mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcBNtNf
Q4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6BczTt
bfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8ncFLQ
DHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtDJCjM
RyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZBk1Av
csr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vXVOEV
p1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBukJU5g
4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5cokKb5
RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaYVk5p
5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgAAAAh
AJStDd/UAAAArAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJl
bHOskL9qAzEMh/dC38For3WXIZQSX5YSyBqSBxC2zuf0/AfbCc3b122WHgS6dBFIQp8+fpvtp5/F
lXNxMSjoZQeCg47GBavgdNy9vIIolYKhOQZWcOMC2+H5aXPgmWo7KpNLRTRKKAqmWtMbYtETeyoy
Jg5tM8bsqbY2W0ykP8gyrrpujfk3A4YFU+yNgrw3KxDHW2qf/2bHcXSa36O+eA71wQuszYsbkLLl
qkDK++Ree9lcAR9r9P+p4XyLYKHh2TjCn3kvz4nttwcuMh6+AAAA//8DAFBLAQItABQABgAIAAAA
IQDI4TOSFQEAAFICAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0A
FAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAARgEAAF9yZWxzLy5yZWxzUEsBAi0A
FAAGAAgAAAAhAHOnKNoaAwAA+gcAAB8AAAAAAAAAAAAAAAAAMAIAAGNsaXBib2FyZC9kcmF3aW5n
cy9kcmF3aW5nMS54bWxQSwECLQAKAAAAAAAAACEAXtaWXXINAAByDQAAGwAAAAAAAAAAAAAAAACH
BQAAY2xpcGJvYXJkL21lZGlhL2ltYWdlMS5qcGVnUEsBAi0AFAAGAAgAAAAhAOFRNx/PBgAA5hsA
ABoAAAAAAAAAAAAAAAAAMhMAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgA
AAAhAJStDd/UAAAArAEAACoAAAAAAAAAAAAAAAAAORoAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVs
cy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABgAGALABAABVGwAAAAA=
">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_2" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;width:32186;height:21945;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/user/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
 </v:shape><v:shape id="Graphic_x0020_3" o:spid="_x0000_s1028" style='position:absolute;
  top:22021;width:32188;height:13;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="3218815,1270" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l3218688,e" filled="f" strokecolor="#fcfcfc" strokeweight=".42331mm">
  <v:path arrowok="t"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="340" height="232" src="file:///C:/Users/user/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:253.45pt;height:174pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 1: Possible infusion sites for Hizentra</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Infusion Rate</em></strong></p><p><u>Replacement Therapy</u></p><p>The recommended initial infusion rate depends on the individual needs of the patient and should not exceed 15 mL/hour/site. If well tolerated, the infusion rate may then be gradually increased up to</p><p>25 mL/hour/site.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</u></p><p>The recommended initial infusion rate depends on the individual needs of the patient and should not exceed 20 mL/hour/site. If well tolerated, the infusion rate may then be gradually increased up to</p><p>50 mL/hour/site.</p><p>When administered every two weeks, the required Hizentra volume can be delivered if necessary in up to 4 sessions, e.g. once in the morning and once in the evening on 2 consecutive days or any other days of the second week.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or any of the excipients according to the composition (see section “Composition”).
Hyperprolinaemia type I or II. Hyperprolinaemia is an extremely rare disorder. Only a few families with this disease are known worldwide.
Hizentra must not be given intravascularly.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If Hizentra is accidentally administered into a blood vessel, patients may go into shock.</p><p>&nbsp;</p><p>&nbsp;</p><p>The recommended infusion rate given under section &ldquo;Posology/method of administration: <em>Infusion rate</em>&rdquo; should be adhered to. Patients should be closely monitored during their first supervised infusions for any adverse events during the infusion period and for at least 20 minutes thereafter.</p><p>&nbsp;</p><p>Certain adverse reactions may occur more frequently in patients who receive human immunoglobulin for the first time or, in rare cases, when the human immunoglobulin product has been switched or treatment stopped for more than eight weeks.</p><p>&nbsp;</p><p><u>Hypersensitivity/anaphylactic reactions</u></p><p>True allergic reactions are rare. They can occur in patients with anti-IgA antibodies. Patients with anti- IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be switched to Hizentra only under close medical supervision.</p><p>Rarely, the administration of human immunoglobulin can induce a sudden fall in blood pressure with an anaphylactic reaction, even in patients who have tolerated previous treatment with human immunoglobulin.</p><p>&nbsp;</p><p>Potential complications can often be avoided by ensuring that patients:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not sensitive to human immunoglobulin, by initially injecting the product slowly (&le; 15 mL/hour/site);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are carefully monitored for any symptoms throughout the infusion period and for at least 20 minutes after administration. In particular, patients naive to human immunoglobulin, patients switched from another immunoglobulin preparation or patients who have not been treated for a long interval since the previous infusion should be monitored during the first infusion and for the first hour thereafter in order to detect potential adverse signs.</p><p>&nbsp;</p><p>If there is any suspicion of allergic or anaphylactic type reactions the infusion must be immediately discontinued. In the event of shock, standard medical treatment should be administered.</p><p>&nbsp;</p><p><u>Embolic and thromboembolic events</u></p><p>There is clinical evidence of an association between the immunoglobulin administration and embolic/thromboembolic events such as myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism. Particular caution should be therefore exercised in patients with pre-existing risk factors for thrombotic events (e.g. advanced age, hypertension, diabetes mellitus, history of vascular disease or thrombotic episodes, acquired or inherited thrombophilic disorders, prolonged</p><p>&nbsp;</p><p>periods of immobilization, severe hypovolaemia, and diseases which increase blood viscosity). Patients should be informed about first symptoms of thromboembolic events such as shortness of breath, pain and swelling of limbs, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms. Patients should be sufficiently hydrated before use of immunoglobulins.</p><p>&nbsp;</p><p><u>Aseptic Meningitis Syndrome (AMS)</u></p><p>AMS cases have occurred with use of intravenous or subcutaneous immunoglobulin. The syndrome usually begins within several hours to 2 days following immunoglobulin treatment. AMS is characterised by the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea and vomiting. Patients exhibiting signs and symptoms of AMS should receive a thorough neurological examination, including CSF tests, to rule out other causes of meningitis. Discontinuation of immunoglobulin treatment results in remission of AMS within several days without sequelae.</p><p>&nbsp;</p><p><u>Renal complications</u></p><p>Cases of severe adverse reactions affecting the kidneys have been reported in patients receiving immunoglobulin therapy, in particular with preparations containing sucrose (Hizentra does not contain any sucrose). These reactions include acute renal failure, acute tubular necrosis, proximal tubulopathy and osmotic nephrosis. Factors which increase the risk of renal complications include, among others, existing renal insufficiency, diabetes mellitus, hypovolaemia, nephrotoxic co-medications, age over 65, sepsis, hyperviscosity and paraproteinaemia.</p><p>&nbsp;</p><p><u>Haemolytic anaemia</u></p><p>Immunoglobulin products can contain blood group antibodies that may act as haemolysins and induce <em>in vivo </em>coating of red blood cells with immunoglobulin. This may cause a positive direct antiglobulin reaction (DAT, direct Coombs test) and, rarely, haemolysis. Delayed haemolytic anaemia can develop subsequent to IgG therapy due to enhanced RBC sequestration. Haemolytic anaemia has been reported.</p><p>&nbsp;</p><p>Information on safety with respect to transmissible agents</p><p>Hizentra is made from human plasma. Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses (see section &ldquo;Properties/Effects&rdquo;).</p><p>Nevertheless, when medicinal products prepared from human blood or plasma are administered, the</p><p>&nbsp;</p><p>possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>&nbsp;</p><p>The measures taken are considered effective for enveloped viruses such as the human immunodeficiency virus (HIV), the hepatitis B virus (HBV) and the hepatitis C virus (HCV), and for the non-enveloped viruses such as the hepatitis A virus (HAV) and parvovirus B19.</p><p>&nbsp;</p><p>There is reassuring clinical experience regarding the lack of HAV or parvovirus B19 transmission with immunoglobulins: it is also assumed that the antibody content makes an important contribution to viral safety.</p><p>&nbsp;</p><p>It is recommended that whenever Hizentra is administered to a patient the name and batch number of the medicinal product are recorded in order to maintain a link between the patient and medicinal product batch.</p><p>&nbsp;</p><p>Hizentra contains less than 1 mmol of sodium (23 mg) per pre-filled syringe; that is to say, it is almost &ldquo;free of sodium&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Live attenuated virus vaccines</p><p>Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, mumps, rubella and varicella. After administration of this medicinal product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles vaccine, this impairment may persist for up to 1 year. Patients receiving measles vaccine should therefore have their antibody status checked.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data from prospective clinical trials on the use of Hizentra in pregnant women and breast-feeding women is available. Hizentra should therefore only be given with caution to pregnant women and breast-feeding mothers. Long-term clinical experience with immunoglobulins suggests however that no harmful effects on the course of pregnancy, or on the foetus or neonate are to be expected.</p><p>&nbsp;</p><p>Continued treatment of the pregnant woman is important to ensure that the neonate is born with appropriate passive immunity.</p><p>&nbsp;</p><p>Immunoglobulins are excreted into breast milk and may contribute to the transfer of protective antibodies to the neonate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ability to drive and operate machines may be impaired by some adverse reactions associated with Hizentra. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Adverse drug reactions (ADR) such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate back pain may occur occasionally in association with human immunoglobulin medication.</p><p>&nbsp;</p><p>Rarely human immunoglobulins may cause a sudden fall in blood pressure and in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.</p><p>&nbsp;</p><p>Local reactions at infusion sites: swelling, soreness, redness, induration, local heat, itching, bruising and rash.</p><p>&nbsp;</p><p><u>Adverse drug reactions (ADRs) collected from clinical trials and post marketing observations with</u> <u>Hizentra:</u></p><p>In seven phase III studies in patients with primary immunodeficiency (n = 231) and two phase III studies with CIDP patients (n = 197) with Hizentra, (total n = 428) the following ADRs were reported and are summarised and categorised below according to the MedDRA System Organ Class and frequency.</p><p>Frequencies per patient have been evaluated using the following criteria: very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). The frequency of spontaneous ADRs after its marketing launch is reported as isolated cases.</p><p>&nbsp;</p><p><em>Infections and infestations</em></p><p>Very common: Nasopharyngitis (20.3%)</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders:</em></p><p>&nbsp;</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood lactate dehydrogenase increased Isolated cases: Haemolytic anaemia**</p><p>&nbsp;</p><p><em>Immune system disorders:</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Isolated cases: Anaphylactic reactions</p><p>&nbsp;</p><p><em>Nervous system disorders:</em></p><p>Very common: Headache (including migraine) (14.0%) Common:&nbsp; Dizziness</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptic meningitis syndrome (AMS)*, tremor (including psychomotor hyperactivity) Isolated cases: Burning sensation, somnolence</p><p>&nbsp;</p><p><em>Cardiac disorders:</em></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia (including blood pressure increase)</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Vascular disorders:</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flushes, aldolase increase</p><p>Isolated cases: Embolic- and thromboembolic events (including thrombosis, embolism, transient ischaemic attack, hemiparesis, transient blindness, haemorrhagic cerebral infarction, hemiplegia)</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders:</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Gastrointestinal disorders:</em></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, abdominal pain, nausea, vomiting</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Skin</em><em> </em><em>and subcutaneous</em><em> </em><em>tissue</em><em> </em><em>disorders:</em></p><p>Very common: Rash (including erythema) (10.7%) Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus, urticarial, contact dermatitis</p><p>&nbsp;</p><p><em>Musculoskeletal, connective tissue and bone disorders:</em></p><p>Very common: Musculoskeletal pain (including muscle spasm and muscular weakness) (11.4%) Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthritis</p><p>&nbsp;</p><p>Uncommon: Serum creatine phosphokinase increased</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>and</em><em> </em><em>urinary</em><em> </em><em>disorders</em>:</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haematuria, raised creatinine</p><p>Isolated cases: Acute renal failure**, acute tubular necrosis**, proximal&nbsp;&nbsp; tubulopathy** und osmotic nephrosis **</p><p>&nbsp;</p><p><em>General disorders and administration site conditions:</em></p><p>Very common: Local reactions at the infusion site, (including bruising and haematoma) (43.9%) Common:&nbsp;&nbsp;&nbsp;&nbsp; Fever (including body temperature increase), tiredness (including general malaise),</p><p>chest pain, flu-like illness, pains Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills (including hypothermia), weight loss Isolated cases: Ulcer at the infusion site</p><p>&nbsp;</p><p>*Aseptic Meningitis Syndrome (ASM) symptoms include: stiff neck, headache, pyrexia, photophobia, nausea, and vomiting.</p><p>**Adverse immunoglobulin class effects.</p><p>&nbsp;</p><p>&nbsp;</p><p>Information on virus safety: see chapter &ldquo;Warnings and Precautions&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any new or suspected adverse reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong>Saudi</strong><strong> </strong><strong>Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p><p>&nbsp;</p><p>Other GCC States:</p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consequences of an overdose are not known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ATC code: </em>J06BA01</p><p>Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration.</p><p>&nbsp;</p><p>1.1&nbsp;&nbsp; Mechanism of action/pharmacodynamics</p><p>Hizentra contains a broad spectrum of opsonising and neutralising IgG antibodies against a large number of bacterial and viral pathogens.</p><p>Hizentra contains the immunoglobulin G antibodies present in the average population. It is prepared from plasma from not less than 1000 donors. The IgG subclass distribution roughly equals that of unprocessed human plasma.</p><p>&nbsp;</p><p>Sufficient Hizentra doses can raise low IgG antibody levels to normal levels and thus help to combat infections.</p><p>The mechanism of action of Hizentra in patients with CIDP is not fully understood, but may include immunomodulatory effects.</p><p>&nbsp;</p><p>Clinical efficacy</p><p><u>Primary Immunodeficiency Syndromes</u></p><p>The safety and efficacy of Hizentra in patients with primary immunodeficiency syndromes has been assessed in four prospective open-label, single-arm and multicentre studies in Europe and the US. In the European pivotal study, a total of 51 subjects with primary immunodeficiency syndromes aged between 3 and 60 years old were treated with Hizentra for up to 41 weeks. The mean dose administered each week was 119 mg/kg body weight. Sustained IgG trough levels with mean concentrations of 7.99 &ndash; 8.25 g/L were thereby achieved throughout the treatment period. Subjects received in total 1831 weekly Hizentra infusions.</p><p>&nbsp;</p><p>In the subsequent extension study a total of 40 patients treated previously in the pivotal study (age 4 - 52 years) were enrolled and treated for up to 46 months at the same dose. Patients received a total of 5405 weekly Hizentra infusions.</p><p>Over the entire treatment period constant IgG trough levels were achieved with average concentrations of 7.5 &ndash; 8.5 g/L, thus confirming the results of the pivotal study. The rate of acute serious bacterial infections (aSBI) was 0.0478 per patient per year, with an upper 99% confidence interval (CI) of 0.1252.</p><p>&nbsp;</p><p>In the US study, a total of 49 subjects with primary immunodeficiency syndromes aged between 5 and 72 years old were treated with Hizentra for up to 15 months. The mean dose administered each week was 228 mg/kg body weight. Sustained IgG trough levels with a mean concentration of 12.53 g/L were thereby achieved throughout the treatment period. Subjects received in total 2264 weekly Hizentra infusions.</p><p>&nbsp;</p><p>In the subsequent US extension study, a total of 21 previously treated patients (aged 5 - 69 years) were enrolled and treated for up to 87 weeks at the same dose. Patients received a total of 1735 weekly Hizentra infusions.</p><p>Over the entire treatment period constant IgG trough levels were achieved with average concentrations of 11.71 &ndash; 12.76 g/L (overall average 11.98 g/L), thus confirming the results of the pivotal study. IgG trough levels never fell below 5 g/L during administration in any of the treated patients. The aSBI rate was 0.06 per patient per year, with an upper 99% confidence interval of 0.257.</p><p>&nbsp;</p><p><u>Children and adolescents</u></p><p>The safety and efficacy of Hizentra has been examined in paediatric patients aged between 2 and 18 years.</p><p>Hizentra was evaluated in 54 paediatric PID patients aged 2 to &lt;12 years in 45 paediatric patients aged 12 to &lt;18 years.</p><p>No differences were established between adult and paediatric patients in terms of pharmacokinetic parameters, safety or efficacy. In paediatric patients, no specific dose was necessary in order to achieve the desired serum IgG levels.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>With regard to safety and efficacy, no differences were observed overall between PID patients older than 65 years and PID patients aged 18 to 65 years. In the clinical studies, Hizentra was investigated in 9 PID patients older than 65 years.</p><p>&nbsp;</p><p><u>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</u></p><p>The safety, efficacy and tolerability of Hizentra in patients with CIDP was evaluated in a multicentre, double-blind, randomised, placebo-controlled, parallel-group phase III study - PATH [Polyneuropathy and Treatment with Hizentra]. 172 previously IVIg-treated subjects were randomized into groups receiving weekly doses of 0.2 g/kg body weight of Hizentra, 0.4 g/kg body weight of Hizentra or placebo and subsequently treated for 24 weeks. The average duration of exposure was 118.9 days in the 0.2 g/kg body weight group and 129 days in the 0.4 g/kg body weight group (maximum exposure in each group up to 167 days and 166 days, respectively). The study participants generally used 4 infusion sites simultaneously (up to 8 sites at a time).</p><p>&nbsp;</p><p>A total of 57 study participants received 1514 infusions in the placebo group, 57 study participants received 2007 infusions in the Hizentra group at 0.2 g/kg body weight, and 58 study participants received 2218 infusions in the Hizentra group at 0.4 g/kg body weight (a total of 5739 infusions).</p><p>&nbsp;</p><p>The primary efficacy endpoint was the percentage of subjects who had CIDP recurrence (defined as an increase of &ge; 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scale versus the baseline) or who, for some other reason, were removed from the Hizentra treatment phase. Both Hizentra doses were superior to placebo for the primary efficacy endpoint.</p><p>A statistically significantly lower percentage of Hizentra-treated patients had recurrent CIDP or were withdrawn from the study for other reasons: 32.8% for 0.4 g/kg body weight and 38.6% for 0.2 g/kg body weight compared to 63.2% of placebo-treated subjects [p &lt;0.001 and p = 0.007 respectively]. When recurrent cases were considered in isolation, CIDP recurrence rates were 19.0% for Hizentra at</p><p>0.4 g/kg body weight and 33.3% for 0.2 g/kg body weight Hizentra versus 56.1% for placebo</p><p>(p &lt; 0.001 and p = 0.012 respectively). Over a treatment period of up to 24 weeks, Hizentra thus prevented recurrence in 81% and 67% of study participants in the 0.4 g/kg body weight and 02 g/kg body weight groups respectively. In the placebo group, no recurrence occurred in 44% of the study participants.</p><p>The time to CIDP recurrence was evaluated and corresponding probabilities for CIDP recurrence based on Kaplan-Meier estimates were: placebo 58.8%; 0.2/kg body weight Hizentra 35.0% and 0.4 g</p><p>/ kg body weight Hizentra 22.4%. The hazard ratios (95% CI) for the lower and higher dose compared to placebo were 0.48 (0.27; 0.85) and 0.25 (0.12; 0.49), respectively. The observed difference between the 0.2 g/kg body weight Hizentra group and the 0.4 g/kg body weight Hizentra group did not attain statistical significance.</p><p>Study participants remained stable in the efficacy outcomes (INCAT scale, average grip and mean Medical Research Council (MRC) scale) in both Hizentra dosing groups compared to study participants in the placebo group, whose outcomes worsened. Study participants in the high-dose Hizentra group remained stable on Rasch&#39;s percentile Overall Disability Scale (R-ODS).</p><p>Electrophysiological parameters remained stable for study participants in both Hizentra dose groups.</p><p>&nbsp;</p><p>&nbsp;</p><p>82 CIDP patients from the PATH study were included in the multicentre, 48-week, open-label phase III extension study. In the extension study, the long-term safety and efficacy of Hizentra maintenance therapy with two different weekly doses of 0.2 g/kg or 0.4 g/kg body weight was investigated. As a result of the study design, the same patient was able to receive both doses during the study, 72 patients received a dose of 0.4 g/kg body weight and 73 patients received a dose of 0.2 g/kg. The mean duration of the treatment was 125.8 days (range: 1-330) in the group with 0.2 g/kg body weight and</p><p>196.1 days (range 1-330) in the group with 0.4 g/kg body weight.</p><p>&nbsp;</p><p>Patients who had completed the pivotal PATH study without a recurrence with a dose of 0.4 g/kg body weight and initially received this dose in the extension study had a rate of recurrence of 5.6% (1 out of 18 patients).</p><p>Of all patients who had received 0.4 g/kg body weight in the PATH extension study, 9.7% (7 out of 72 patients) experienced a recurrence.</p><p>The patients who had completed the PATH study without a recurrence with 0.2 g/kg body weight and initially received this dose in the extension study had a rate of recurrence of 50% (3 out of 6 patients). Of all patients who received 0.2 g/kg body weight in the extension study, 47.9% (35 out of 73 patients) experienced a recurrence. The reduction in the dose from 0.4 g/kg body weight to 0.2 g/kg body weight in the extension study without a recurrence was possible in 67.9% of patients (19 out of 28 patients). All patients who experienced a recurrence recovered within 4 weeks of treatment with</p><p>0.4 g/kg body weight.</p><p>Grip strength, the total number of points on the MRC Scale and the R-ODS centile score remained stable compared with baseline in patients who did not experience a recurrence in the extension study.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Treatment of paediatric CIDP patients with Hizentra has not been evaluated in clinical studies.</p><p>&nbsp;</p><p>&nbsp;</p><p>Elderly patients</p><p>There were no overall differences in safety and efficacy between patients older than 65 years and patients aged 18 to 65 years. In the clinical studies with CIDP patients, 61 people older than 65 years were treated with Hizentra.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following subcutaneous administration of Hizentra, peak IgG serum levels are achieved after approximately 2 days.</p><p>IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Primary Immunodeficiency Syndromes</u></p><p>Simulations with population-pharmacokinetic&nbsp;models suggest that a comparable&nbsp;IgG exposure (Cmax, AUC0-14days, Cmin, 14 days) is achieved when the double weekly Hizentra dose is administered every two weeks. These simulations further suggest that a comparable IgG exposure is achieved when the weekly maintenance dose of Hizentra is divided in several doses (e.g. 2, 3 or 5 times per week or daily).</p><p>&nbsp;</p><p>If 2-3 daily doses are missed during continuous daily dosing, simulations suggest that this results in a mean serum IgG level decrease of about &le; 4% compared to consistent daily dosing. By subsequent administration of the missed doses at the first day in addition to the daily dose, when daily dosing is resumed, the median IgG concentration profile recovers within 2 - 3 days. However, if the missed doses are not replaced when dosing is resumed, steady-state IgG trough levels are only attained after a treatment time of up to 5-6 weeks.</p><p>&nbsp;</p><p>Children and adolescents</p><p>No differences in pharmacokinetic parameters have been established between adult and paediatric PID subjects.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Overall, no differences in the pharmacokinetic parameters of PID patients aged &gt;65 years and aged 18 to 65 years have been observed.</p><p>&nbsp;</p><p><u>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</u></p><p>In the PATH study, study participants (n = 172) achieved sustained trough values over a period of 24 weeks when receiving weekly doses of 0.2 g/kg body weight or 0.4 g / kg body weight. The mean (SD) IgG-trough concentrations after a Hizentra treatment were 20.4 (3.24) g/L in the group receiving</p><p>0.4 g/kg body weight and 15.4 (3.06) g/L in the group receiving 0.2 g/kg body weight. Simulations with population-pharmacokinetic models in the PATH Study suggest that a comparable IgG exposure (Cmax, AUC0-14 days, Cmin, 14 days) is achieved if the CIDP study participants are given double the Hizentra dose every two weeks. These simulations lead to the further assumption that a comparable IgG exposure can be similarly achieved in the CIDP patient population if the weekly maintenance dose of Hizentra is divided into several, more frequent doses (2 - 7 times a week).</p><p>&nbsp;</p><p>Children and adolescents</p><p>Treatment of paediatric CIDP patients below 18 years with Hizentra has not been evaluated in clinical studies.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Overall, no differences in the pharmacokinetic parameters were observed between CIDP patients aged</p><p>&gt;65 years and aged 18 to 65 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunoglobulins are a normal constituent of the human body. L-proline is a physiological, non- essential amino acid.</p><p>&nbsp;</p><p>The safety of Hizentra has been assessed in several preclinical studies, with particular reference to the excipient L-proline. Preclinical data revealed no special risk for humans based on safety pharmacology and toxicity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Please see section 2 b.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p><p>&nbsp;</p><p>&nbsp;</p><p>Interference with diagnostic methods</p><p>After immunoglobulin infusion the transient rise in various passively transferred antibodies in the patient&#39;s blood may result in false positive results on serological testing.</p><p>&nbsp;</p><p>Passive transmission of antibodies against erythrocyte antigens, e.g. A, B and D, may interfere with some serological tests for red cell allo-antibodies (e.g. Coombs test), reticulocyte counts and haptoglobin tests.</p><p>&nbsp;</p><p>Interactions with live attenuated vaccines: see section &ldquo;Interactions&ldquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
Hizentra can be stored until the expiry date printed on the label and outer carton after “EXP”. Do not use the medicinal product after the expiry date (EXP).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25 C. Do not freeze. Keep out of the reach and sight of children.</p><p>Keep the blistered pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Shelf life after opening the package:</u></p><p>Hizentra is intended for single-use only. Because the solution contains no preservative, Hizentra should be administered as soon as possible after opening the pre-filled syringe.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5, 10, 20 or 50 ml of solution in a pre-filled syringe (cyclo-olefin-copolymer (COC)) with mounted bromobutyl tipcap and closed with a bromobutyl plunger.</p><p>&nbsp;</p><p>Pack sizes</p><p>1 x 5 ml (1g) pre-filled syringe 1 x 10 ml (2g) pre-filled syringe 1 x 20 ml (4g) pre-filled syringe</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hizentra is provided as a ready-to-use solution in single-use pre-filled syringes. The medicinal product should be at room or body temperature before use.</p><p>&nbsp;</p><p>The solution should be clear and pale-yellow or light-brown. Do not use if the solution is cloudy or has particulate matter.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CSL Behring AG Wankdorfstrasse 10
3014 Bern Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2019


Note: Hizentra ® is a registered trademark of CSL Behring AG in many countries.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>